Page last updated: 2024-10-18

glycine and Neoplasms

glycine has been researched along with Neoplasms in 233 studies

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
" The hyperhomocysteinemia, suppressed immunity, and altered oxidative metabolism observed in atherosclerosis and dementia are attributed to deficiency of adenosyl methionine which results from increased polyamine biosynthesis by pathogenic microbes that are demonstrated in atherosclerotic plaques and cerebral plaques."9.05Environmental Pollution, Oxidative Stress and Thioretinaco Ozonide: Effects of Glyphosate, Fluoride and Electromagnetic Fields on Mitochondrial Dysfunction in Carcinogenesis, Atherogenesis and Aging. ( McCully, KS, 2020)
"Glycine protects skeletal muscle from cancer-induced wasting and loss of function, reduces the oxidative and inflammatory burden, and reduces the expression of genes associated with muscle protein breakdown in cancer cachexia."7.80Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. ( Chee, A; Ham, DJ; Koopman, R; Lynch, GS; Murphy, KT, 2014)
"In patients with solid tumors, ixazomib was associated with a manageable safety profile, limited antitumor activity, and evidence of downstream proteasome inhibition effects."6.80Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. ( Berg, D; Berger, AJ; Di Bacco, A; Gao, F; Gupta, N; Hui, AM; Infante, JR; Kalebic, T; Kauh, JS; Lin, J; Liu, G; Siu, LL; Smith, DC; Sullivan, D; Thompson, JA; Tirrell, S; Vlahovic, G, 2015)
"Glyphosate has been detected in urine, blood and maternal milk and has been found to induce the generation of reactive oxygen species (ROS) and several cytotoxic and genotoxic effects in vitro and in animal models directly or indirectly through its metabolite, aminomethylphosphonic acid (AMPA)."6.72Pleiotropic Outcomes of Glyphosate Exposure: From Organ Damage to Effects on Inflammation, Cancer, Reproduction and Development. ( Marino, M; Meccariello, R; Mele, E; Nori, SL; Santoro, A; Viggiano, A, 2021)
" The hyperhomocysteinemia, suppressed immunity, and altered oxidative metabolism observed in atherosclerosis and dementia are attributed to deficiency of adenosyl methionine which results from increased polyamine biosynthesis by pathogenic microbes that are demonstrated in atherosclerotic plaques and cerebral plaques."5.05Environmental Pollution, Oxidative Stress and Thioretinaco Ozonide: Effects of Glyphosate, Fluoride and Electromagnetic Fields on Mitochondrial Dysfunction in Carcinogenesis, Atherogenesis and Aging. ( McCully, KS, 2020)
"This systematic review and meta-analysis rigorously examines the relationship between glyphosate exposure and risk of lymphohematopoietic cancer (LHC) including NHL, Hodgkin lymphoma (HL), multiple myeloma (MM), and leukemia."4.93Systematic review and meta-analysis of glyphosate exposure and risk of lymphohematopoietic cancers. ( Chang, ET; Delzell, E, 2016)
"Glycine protects skeletal muscle from cancer-induced wasting and loss of function, reduces the oxidative and inflammatory burden, and reduces the expression of genes associated with muscle protein breakdown in cancer cachexia."3.80Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. ( Chee, A; Ham, DJ; Koopman, R; Lynch, GS; Murphy, KT, 2014)
"The proteasome was validated as an oncology target following the clinical success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma."3.76Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. ( Bannerman, B; Berger, A; Blank, J; Bolen, J; Bruzzese, F; Cao, Y; Dick, L; Fitzgerald, M; Fleming, P; Garcia, K; Hales, P; Kupperman, E; Lee, EC; Liu, J; Manfredi, M; Rolfe, M; Tsu, C; Yang, Y; Yu, J; Yu, L, 2010)
"Anemia is a common side effect of myelosuppressive chemotherapy; however, chemotherapy-induced anemia (CIA) management options are suboptimal."3.30Open-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies. ( Gabrail, NY; Glaspy, J; Henry, DH; Lee, T; Locantore-Ford, P; Modelska, K; Samal, V, 2023)
" We explored the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of ivosidenib in these populations."2.94Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. ( Agresta, S; Dai, D; Fan, B; Gliser, C; Goyal, L; Jiang, L; Liu, G; Lowery, MA; Manyak, E; Mellinghoff, IK; Nimkar, T; Pandya, SS; Prahl Judge, M; Tap, WD; Wen, PY; Yang, H, 2020)
" The clinical drug-drug interaction study results were reconciled well by a physiologically based pharmacokinetic model that incorporated a minor contribution of CYP3A to overall ixazomib clearance and quantitatively considered the strength of induction of CYP3A and intestinal P-glycoprotein by rifampin."2.87Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Ana ( Bessudo, A; Esseltine, DL; Gupta, N; Hanley, MJ; Ke, A; Liu, G; Nemunaitis, J; O'Neil, BH; Patel, C; Rasco, DW; Rowland Yeo, K; Sharma, S; Venkatakrishnan, K; Wang, B; Xia, C; Zhang, X, 2018)
"Conventional therapies for malignant tumors have limitations and disadvantages."2.82Current status of cancer starvation therapy. ( Li, J; Lin, J; Tong, D, 2022)
"We examine the implications of αVβ6 in cancer progression and the promotion of epithelial-mesenchymal transition (EMT) by contributing to the activation of transforming growth factor beta TGF-β."2.82Integrin Alpha v Beta 6 (αvβ6) and Its Implications in Cancer Treatment. ( Brzozowska, E; Deshmukh, S, 2022)
"Eligible adults with advanced malignancies for which no further effective therapy was available received a single dose of ixazomib on day 1 of the pharmacokinetic cycle; patients with normal hepatic function, moderate hepatic impairment or severe hepatic impairment received 4 mg, 2."2.82Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. ( Falchook, G; Fu, S; Gupta, N; Hanley, MJ; Labotka, R; Nemunaitis, J; Norris, RE; Perez, R; Qian, MG; Venkatakrishnan, K; Yang, H, 2016)
"In patients with solid tumors, ixazomib was associated with a manageable safety profile, limited antitumor activity, and evidence of downstream proteasome inhibition effects."2.80Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. ( Berg, D; Berger, AJ; Di Bacco, A; Gao, F; Gupta, N; Hui, AM; Infante, JR; Kalebic, T; Kauh, JS; Lin, J; Liu, G; Siu, LL; Smith, DC; Sullivan, D; Thompson, JA; Tirrell, S; Vlahovic, G, 2015)
"Archival tumors were assessed for potential molecular biomarkers with multiplex mutation testing."2.79Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. ( Aisner, DL; Anderson, RT; Astling, DP; Bowles, DW; Diamond, JR; Eckhardt, SG; Freas, E; Gore, L; Jimeno, A; Keysar, SB; Lam, ET; Leong, S; Maniar, M; Messersmith, WA; Ren, C; Tan, AC; Varella-Garcia, M; Vogler, BW; Weekes, CD; Wilhelm, F, 2014)
"Gemcitabine was administered on days 1, 8, and 15 on a 28-day cycle and rigosertib on days 1, 4, 8, 11, 15, and 18."2.77Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. ( Adjei, AA; Dy, GK; Eckhardt, SG; Jimeno, A; Ma, WW; Maniar, M; Messersmith, WA; Ren, C; Weekes, CD; Whitworth, A; Wilhelm, F, 2012)
"This Phase Ib dose-escalating study investigated safety, maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and clinical antitumour activity of tosedostat (CHR-2797), an orally bioavailable aminopeptidase inhibitor, in combination with paclitaxel."2.75A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours. ( Bone, EA; de Jonge, M; Desar, I; Eskens, FA; Hooftman, L; Timmer-Bonte, JN; van Herpen, CM; Verweij, J, 2010)
" The terminal half-life for CHR-2797 is approximately 1 to 3."2.74A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. ( Attard, G; Bone, EA; Carter, J; De Bono, JS; Harris, A; Hayward, N; Hooftman, L; Protheroe, A; Reid, AH; Shaw, HM; Spicer, J; Vidal, L, 2009)
"Patients had solid tumors refractory to standard therapy."2.73Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. ( Baker, SD; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, D; Li, J; Maniar, M; Messersmith, WA; Rudek, MA, 2008)
"Glyphosate has been detected in urine, blood and maternal milk and has been found to induce the generation of reactive oxygen species (ROS) and several cytotoxic and genotoxic effects in vitro and in animal models directly or indirectly through its metabolite, aminomethylphosphonic acid (AMPA)."2.72Pleiotropic Outcomes of Glyphosate Exposure: From Organ Damage to Effects on Inflammation, Cancer, Reproduction and Development. ( Marino, M; Meccariello, R; Mele, E; Nori, SL; Santoro, A; Viggiano, A, 2021)
"Here, we review its role in cancer by focusing on key enzymes with tumor-promoting functions and important products of the SGOCP that are of physiological relevance for tumorigenesis."2.66The complexity of the serine glycine one-carbon pathway in cancer. ( Diaz-Meco, MT; Moscat, J; Reina-Campos, M, 2020)
" The test statistics for these permutation tests are functions of p values from a standard test for dose-response trend applied to each specific type of tumor."2.66Accounting for Multiple Comparisons in Statistical Analysis of the Extensive Bioassay Data on Glyphosate. ( Crouch, E; Crump, C; Crump, K; Haseman, J; Zelterman, D, 2020)
"Serine encounters diverse fates in cancer cells, including being charged onto tRNAs for protein synthesis, providing head groups for sphingolipid and phospholipid synthesis, and serving as a precursor for cellular glycine and one-carbon units, which are necessary for nucleotide synthesis and methionine cycle reloading."2.66Reprogramming of serine, glycine and one-carbon metabolism in cancer. ( Li, AM; Ye, J, 2020)
"Metabolic reprogramming in cancer cells entails activities that involve several enzymes and metabolites to convert nutrient into building blocks that alter energy metabolism to fuel rapid cell division."2.66Cancer Cell Metabolites: Updates on Current Tracing Methods. ( Maniam, S, 2020)
"The objective of this review is to evaluate the mechanism of activity, efficacy and dosing of rigosertib."2.49Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. ( Fan, AC; Felsher, DW; O'Rourke, JJ; Praharaj, DR, 2013)
" Presenting adverse effects of glyphosate and its formulations we focused on the role of glyphosate formulations in hormonal disorders by impeding the expression of steroidogenic acute regulatory protein and the inhibition of aromatase activity."2.49[Glyphosate and its formulations--toxicity, occupational and environmental exposure]. ( Bukowska, B; Kwiatkowska, M; Paweł, J, 2013)
"To examine potential cancer risks in humans, we reviewed the epidemiologic literature to evaluate whether exposure to glyphosate is associated causally with cancer risk in humans."2.48Epidemiologic studies of glyphosate and cancer: a review. ( Lundin, JI; Mandel, JS; Mink, PJ; Sceurman, BK, 2012)
"About 80% of human tumors, of various origins, express high levels of PLK transcripts."2.45Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. ( Schöffski, P, 2009)
"The anticancer activity of produced carbon nanomaterial revealed that it inhibited the BTK protein and its downstream pathways, including PLC and Akt proteins, at the cellular level."1.91Identification and Biological Evaluation of a Water-Soluble Fullerene Nanomaterial as BTK Kinase Inhibitor. ( Balin, K; Calvaresi, M; Korzuch, J; Malarz, K; Marforio, TD; Mrozek-Wilczkiewicz, A; Musiol, R; Serda, M, 2023)
"While many cancer cells cultured in a standard tissue culture medium depend on exogenous serine for optimal growth, here we report that these cells are less sensitive to serine/glycine depletion in medium containing physiological levels of metabolites."1.62The impact of physiological metabolite levels on serine uptake, synthesis and utilization in cancer cells. ( Cheung, EC; Driscoll, PC; Hennequart, M; Labuschagne, CF; Legrave, NM; Pilley, SE; Tajan, M; Vousden, KH, 2021)
"Cancer is driven by somatic mutations that result in a cellular fitness advantage."1.62Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals. ( Claeys, A; Luijts, T; Marchal, K; Van den Eynden, J, 2021)
"I then present two exposure-cancer cases, namely talcum powder-ovarian cancer and glyphosate-non-Hodgkin lymphoma, that led to civil lawsuits decided, in the United States, in favor of the claimants."1.56Difficulties in establishing a causal link between chemical exposures and cancer cannot be overcome by court assessments. ( Dragani, TA, 2020)
"Thus, rigosertib kills cancer cells by destabilizing microtubules, in agreement with our original findings."1.56Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent. ( Akhmanova, A; Chen, Y; Cho, MY; Gilbert, LA; Horlbeck, MA; Jost, M; Kampmann, M; Krenning, L; Menchon, G; Prota, AE; Rai, A; Steinmetz, MO; Stern, JJ; Tanenbaum, ME; Weissman, JS, 2020)
"A major hallmark of cancer is a perturbed metabolism resulting in high demand for various metabolites, glucose being the most well studied."1.51Analysis of glucose-derived amino acids involved in one-carbon and cancer metabolism by stable-isotope tracing gas chromatography mass spectrometry. ( Gu, W; Herring, J; Ou, Y; Sowers, ML; Tang, H; Zhang, K; Zhang, W, 2019)
"The mechanisms underlying cancer cachexia - the proximate cause of at least 20% of cancer-related deaths - have until recently remained rather obscure."1.51Nutraceutical targeting of TLR4 signaling has potential for prevention of cancer cachexia. ( Iloki-Assanga, S; Lujany, LML; McCarty, MF, 2019)
"Scientists worldwide endorse IARC cancer evaluations and process."1.48Commentary: IARC Monographs Program and public health under siege by corporate interests. ( Huff, J; Infante, PF; Melnick, R; Vainio, H, 2018)
"Rational and effective cancer prevention activities depend on scientifically sound and unbiased assessments of the carcinogenic potential of suspected agents."1.48On the International Agency for Research on Cancer classification of glyphosate as a probable human carcinogen. ( Tarone, RE, 2018)
"It is a promising target for cancer drug development."1.46Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators. ( Archambault, V; Normandin, K, 2017)
" We have identified a novel (E)-styrylsulfonyl methylpyridine [(E)-N-(2-methoxy-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)pyridin-3-yl)methanesulfonamide (TL-77)] which has shown improved oral bioavailability compared with ON01910."1.42In vitro antitumor mechanism of (E)-N-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methanesulfonamide. ( Bradshaw, TD; Laughton, CA; Lu, T; Wang, S, 2015)
"There were no associations with other cancers."1.42Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. ( Aasly, J; Agalliu, I; Bressman, S; Friedman, E; Giladi, N; Hassin-Baer, S; Inzelberg, R; Marti-Masso, JF; Mirelman, A; Orr-Urtreger, A; Ruiz-Martinez, J; San Luciano, M; Saunders-Pullman, R; Waro, B, 2015)
"The cytotoxicity to cancer cell lines of the fullerene-glycine derivatives was evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) and flow cytometry."1.42Synthesis and properties of novel water-soluble fullerene-glycine derivatives as new materials for cancer therapy. ( Duan, J; Jiang, G; Li, G; Yin, F, 2015)
"Previous work has shown that some cancer cells are highly dependent on serine/glycine uptake for proliferation."1.40Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. ( Labuschagne, CF; Mackay, GM; Maddocks, OD; van den Broek, NJ; Vousden, KH, 2014)
"However, cancer NIR fluorescent sensors are very challenging to develop because they are required to exhibit good specificity and low toxicity as an eligible contrast agent."1.40Synthesis and characterization of a glycine-modified heptamethine indocyanine dye for in vivo cancer-targeted near-infrared imaging. ( Liu, T; Luo, S; Qi, Q; Shi, C; Tan, X; Wang, Y, 2014)
"Recent observations on cancer cell metabolism indicate increased serine synthesis from glucose as a marker of poor prognosis."1.39Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. ( Bertino, JR; Boros, LG; Chan, LL; DiPaola, RS; Dolfi, SC; Dvorzhinski, D; Gounder, M; Hirshfield, KM; Lin, H; Markert, EK; Oltvai, ZN; Qiu, J; Tedeschi, PM; Vazquez, A, 2013)
"Glycine is a nonessential amino acid that is reversibly converted from serine intracellularly by serine hydroxymethyltransferase."1.39Glyphosate and AMPA inhibit cancer cell growth through inhibiting intracellular glycine synthesis. ( Ge, D; Lambrechts, MJ; Li, Q; Liu, S; Xi, M; Yin, R; You, Z; Zhang, Q, 2013)
"We propose that patients whose tumors show this phenotype will be sensitive to folate antagonists targeting thymidylate or purine biosynthesis."1.39Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors. ( Bertino, JR; Tedeschi, PM; Vazquez, A, 2013)
"TICs from primary NSCLC tumors express high levels of the oncogenic stem cell factor LIN28B and GLDC, which are both required for TIC growth and tumorigenesis."1.38Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. ( Ahmed, DA; Ang, HS; Bhakoo, KK; Jayapal, SR; Kaldis, P; Lim, B; Lim, EH; Ma, S; Mitchell, W; Nga, ME; Nichane, M; Noghabi, MS; Pang, YH; Rai, A; Robson, P; Shyh-Chang, N; Sing, WP; Soh, BS; Soo, RA; Sun, LL; Swarup, S; Tai, BC; Tam, J; Tan, C; Thirugananam, A; Umashankar, S; Yang, H; Yu, Q; Zhang, WC, 2012)
"The in vivo anticancer activity study with HT-29 colon cancer cell xenografted mice showed that the intratumorally injected PCC hydrogel inhibited the tumor growth more effectively relative to CPT alone (-29% vs."1.38Injectable poly(organophosphazene)-camptothecin conjugate hydrogels: synthesis, characterization, and antitumor activities. ( Cho, JK; Chun, C; Kuh, HJ; Song, SC, 2012)
"Camptothecins have been characterized as inhibitors of DNA topoisomerase I (TOP1), although a correlation between TOP1 expression and activity is not well established in clinical biopsies."1.36Inhibition of epidermal growth factor receptor-overexpressing cancer cells by camptothecin, 20-(N,N-diethyl) glycinate. ( Efferth, T; Konkimalla, VB, 2010)
"At 30 and 50 mg/kg, the urinary bladder tumors were accompanied by evidence of increased urine solids."1.34Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar. ( Arnold, LL; Cohen, SM; Dominick, MA; Minnema, D; Sanderson, TP; Schilling, BE; Tannehill-Gregg, SH; Ulland, B; Voelker, R; Waites, CR, 2007)
"Glyphosate is a broad-spectrum herbicide that is one of the most frequently applied pesticides in the world."1.33Cancer incidence among glyphosate-exposed pesticide applicators in the Agricultural Health Study. ( Alavanja, MC; Blair, A; De Roos, AJ; Dosemeci, M; Hoppin, JA; Rusiecki, JA; Sandler, DP; Svec, M, 2005)
"Recently, four cancer-associated mutants of the A-alpha subunit have been described: Glu64-->Asp in lung carcinoma, Glu64-->Gly in breast carcinoma, Arg418-->Trp in melanoma, and Delta171 - 589 in breast carcinoma."1.31Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. ( Pham, HT; Ruediger, R; Walter, G, 2001)
"Hypocitrullinemia in lung cancer patients was marked, and possible mechanisms to account for this are discussed."1.27Serum amino acids in weight-losing patients with cancer and tuberculosis. ( De Guel, FJ; Duncan, EJ; Gevers, W; Jardine, L; Levin, L, 1983)
"[15N]Glycine was used as the tracer with a prime to infusion ratio of 1300 to 3300 min and a continuous-infusion rate of 0."1.27Tracer priming in human protein turnover studies with [15N]glycine. ( Brennan, MF; Daly, J; Horowitz, GD; Jeevanandam, M; Lowry, SF; Mihranian, MH; Rose, D, 1985)
"This study suggests that some malignant tumors can increase whole body protein synthesis and turnover in both the malnourished and fed state."1.26Whole body protein synthesis and turnover in normal man and malnourished patients with and without known cancer. ( Brennan, MF; Norton, JA; Stein, TP, 1981)

Research

Studies (233)

TimeframeStudies, this research(%)All Research%
pre-199086 (36.91)18.7374
1990's5 (2.15)18.2507
2000's23 (9.87)29.6817
2010's81 (34.76)24.3611
2020's38 (16.31)2.80

Authors

AuthorsStudies
Kato, S1
Adashek, JJ1
Subbiah, V2
Fu, S3
Sun, M1
Nguyen, L1
Brown, EJ1
Yap, TA1
Karp, DD1
Piha-Paul, SA1
Hong, DS1
Alt, J1
Gori, SS1
Lemberg, KM1
Pal, A1
Veeravalli, V1
Wu, Y1
Aguilar, JMH1
Dash, RP1
Tenora, L1
Majer, P1
Sun, Q1
Slusher, BS1
Rais, R1
Gan, Z1
Zhang, M1
Xie, D1
Wu, X1
Hong, C1
Fu, J1
Fan, L1
Wang, S2
Han, S1
Hennequart, M2
Labuschagne, CF2
Tajan, M2
Pilley, SE1
Cheung, EC2
Legrave, NM1
Driscoll, PC1
Vousden, KH3
Abdollahi, P1
Vandsemb, EN1
Børset, M1
Marino, M1
Mele, E1
Viggiano, A1
Nori, SL1
Meccariello, R1
Santoro, A1
Zarei, M1
Hue, JJ1
Hajihassani, O1
Graor, HJ1
Katayama, ES1
Loftus, AW1
Bajor, D1
Rothermel, LD1
Vaziri-Gohar, A1
Winter, JM1
Li, J4
Tong, D1
Lin, J3
Song, Q1
Yang, W1
Deng, X1
Zhang, Y4
Xing, X1
Chen, W1
Liu, W1
Hu, H1
Brzozowska, E1
Deshmukh, S1
Sun, W1
Zhao, E1
Cui, H1
Rushing, BR2
Fogle, HM2
Sharma, J2
You, M2
McCormac, JP2
Molina, S2
Sumner, S2
Krupenko, NI2
Krupenko, SA2
Glaspy, J1
Gabrail, NY1
Locantore-Ford, P1
Lee, T1
Modelska, K1
Samal, V1
Henry, DH1
Malarz, K1
Korzuch, J1
Marforio, TD1
Balin, K1
Calvaresi, M1
Mrozek-Wilczkiewicz, A1
Musiol, R1
Serda, M1
Qin, W1
Chandra, J1
Abourehab, MAS1
Gupta, N8
Chen, ZS1
Kesharwani, P1
Cao, HL1
Kettle, JG1
Bagal, SK1
Barratt, D1
Bodnarchuk, MS1
Boyd, S1
Braybrooke, E1
Breed, J1
Cassar, DJ1
Cosulich, S1
Davies, M1
Davies, NL1
Deng, C1
Eatherton, A1
Evans, L1
Feron, LJ1
Fillery, S1
Gleave, ES1
Goldberg, FW1
Cortés González, MA1
Guerot, C1
Haider, A1
Harlfinger, S1
Howells, R1
Jackson, A1
Johnström, P1
Kemmitt, PD1
Koers, A1
Kondrashov, M1
Lamont, GM1
Lamont, S1
Lewis, HJ1
Liu, L6
Mylrea, M1
Nash, S1
Niedbala, MJ1
Peter, A1
Phillips, C1
Pike, K1
Raubo, P1
Robb, GR1
Ross, S1
Sanders, MG1
Schou, M1
Simpson, I1
Steward, O1
Dalton, WB1
Helmenstine, E1
Walsh, N1
Gondek, LP1
Kelkar, DS1
Read, A1
Natrajan, R1
Christenson, ES1
Roman, B1
Das, S2
Zhao, L1
Leone, RD1
Shinn, D1
Groginski, T1
Madugundu, AK1
Patil, A1
Zabransky, DJ1
Medford, A1
Lee, J1
Cole, AJ1
Rosen, M1
Thakar, M1
Ambinder, A1
Donaldson, J1
DeZern, AE1
Cravero, K1
Chu, D1
Madero-Marroquin, R1
Pandey, A1
Hurley, PJ1
Lauring, J1
Park, BH1
McCarty, MF2
Iloki-Assanga, S1
Lujany, LML1
Kellert, M1
Lönnecke, P1
Riedl, B1
Koebberling, J1
Hey-Hawkins, E1
Reina-Campos, M1
Diaz-Meco, MT1
Moscat, J1
Wang, Y4
Janku, F1
Piha-Paul, S1
Hess, K1
Broaddus, R1
Shi, N1
Overman, M1
Kopetz, S1
Naing, A1
Hong, D1
Tsimberidou, AM1
Karp, D1
Yao, J1
Dragani, TA1
Xiao, F2
Shao, T1
Jin, G1
Crump, K1
Crouch, E1
Zelterman, D1
Crump, C1
Haseman, J1
Berry, C1
Li, AM1
Ye, J1
Kosciuk, T1
Lin, H2
Rusyn, I2
Chiu, WA1
Wright, FA1
McCully, KS1
Jost, M1
Chen, Y1
Gilbert, LA1
Horlbeck, MA1
Krenning, L1
Menchon, G1
Rai, A2
Cho, MY1
Stern, JJ1
Prota, AE1
Kampmann, M1
Akhmanova, A1
Steinmetz, MO1
Tanenbaum, ME1
Weissman, JS1
Maniam, S2
Yerlikaya, A1
Kanbur, E1
Stanley, BA1
Tümer, E1
Muthusamy, T1
Cordes, T1
Handzlik, MK1
You, L1
Lim, EW1
Gengatharan, J1
Pinto, AFM1
Badur, MG1
Kolar, MJ1
Wallace, M1
Saghatelian, A1
Metallo, CM1
Wei, J1
Shi, Z1
Na, R1
Wang, CH1
Resurreccion, WK1
Zheng, SL1
Hulick, PJ1
Cooney, KA1
Helfand, BT1
Isaacs, WB1
Xu, J3
Zani, F1
Hock, AK1
Legrave, N1
Maddocks, ODK1
Ridgway, RA1
Athineos, D1
Suárez-Bonnet, A1
Ludwig, RL1
Novellasdemunt, L1
Angelis, N1
Li, VSW1
Vlachogiannis, G1
Valeri, N1
Mainolfi, N1
Suri, V1
Friedman, A1
Manfredi, M2
Blyth, K1
Sansom, OJ1
Pan, S1
Fan, M1
Liu, Z2
Li, X1
Wang, H4
Geeraerts, SL1
Heylen, E1
De Keersmaecker, K1
Kampen, KR1
Claeys, A1
Luijts, T1
Marchal, K1
Van den Eynden, J1
Zagefka, H1
Huynh, HP1
Senger, AR1
Derington, CG1
Colantonio, LD1
Herrick, JS1
Cook, J1
King, JB1
Rosenson, RS1
Poudel, B1
Monda, KL1
Navar, AM1
Mues, KE1
Stevens, VW1
Nelson, RE1
Vanneman, ME1
Muntner, P1
Bress, AP1
Ma, B1
Ren, G1
Yin, C1
Shi, Y1
Rahsepar, AA1
Bluemke, DA1
Habibi, M1
Liu, K1
Kawel-Boehm, N1
Ambale-Venkatesh, B1
Fernandes, VRS1
Rosen, BD1
Lima, JAC1
Carr, JC1
Freitag, TM1
Chen-Sankey, JC1
Duarte, DA1
Ramsey, MW1
Choi, K1
Winkler-Heil, R1
Hussain, M1
Hofmann, W1
Nicotera, AG1
Dicanio, D1
Pironti, E1
Bonsignore, M1
Cafeo, A1
Efthymiou, S1
Mondello, P1
Salpietro, V1
Houlden, H1
Di Rosa, G1
Hayes-Ryan, D1
O'Donoghue, K1
McCarthy, C1
Totorika, A1
Meaney, S1
Pang, RD1
Dormanesh, A1
Hoang, Y1
Chu, M1
Allem, JP1
Girón-Ortega, JA1
Márquez-Coello, M1
Gutiérrez-Saborido, D1
Arizcorreta, A1
Cuesta-Sancho, S1
Girón-González, JA1
Dovrat, G1
Pevzner, S1
Berthon, C1
Lerner, A1
Maimon, E1
Vainer, R1
Karpasas, M1
Ben-Elyiahu, Y1
Moisy, P1
Bettelheim, A1
Zilbermann, I1
Vanden Broeck, SMP1
Nelson, DJ1
Collado, A1
Falivene, L1
Cavallo, L1
Cordes, DB1
Slawin, AMZ1
Van Hecke, K1
Nahra, F1
Cazin, CSJ1
Nolan, SP1
Kranidiotis-Hisatomi, N1
Yi, H1
Oestreich, M1
Kwiezinski, C1
Weller, C1
van Pinxteren, D1
Brüggemann, M1
Mertes, S1
Stratmann, F1
Herrmann, H1
Treggiari, D1
Tridello, G1
Menin, L1
Borruso, A1
Pintani, E1
Iansa, P1
Cipolli, M1
Melotti, P1
Ren, L2
Shu, X1
Lin, W1
Yang, P1
Chen, J1
Teo, KL1
Yao, T1
Zhao, X1
Yang, X1
Yu, DYW1
Rogach, AL1
Bordet, A1
Leitner, W1
Gao, S1
Xia, F1
Li, B2
Abdul Razak, IB1
Liu, Y3
Lu, K1
Brown, DE1
Wang, R1
Cheng, Y1
Ni, S1
Qu, H1
Xing, H1
Xu, Z1
Zhu, X1
Yuan, M1
Wang, L1
Yu, J2
Li, Y2
Yang, L1
Liu, H1
Cao, L1
Zhang, S2
Zhao, D1
Yan, T1
Yang, G1
Lin, Z1
Luo, M1
Ye, N1
Lee, SW1
Carnicelli, J1
Getya, D1
Gitsov, I1
Phillips, KS1
Ren, D1
Grützmacher, PG1
Suarez, S1
Tolosa, A1
Gachot, C1
Song, G1
Wang, B4
Presser, V1
Mücklich, F1
Anasori, B1
Rosenkranz, A1
Demireva, M1
Armentrout, PB1
Feng, D1
Cao, K1
He, ZZ1
Knibbs, LD1
Jalaludin, B1
Leskinen, A1
Roponen, M1
Komppula, M1
Jalava, P1
Guo, PY1
Xu, SL1
Yang, BY1
Hu, L1
Zeng, XW1
Chen, G1
Yu, HY1
Lin, L1
Dong, G1
Machulkin, AE1
Shafikov, RR1
Uspenskaya, AA1
Petrov, SA1
Ber, AP1
Skvortsov, DA1
Nimenko, EA1
Zyk, NU1
Smirnova, GB1
Pokrovsky, VS1
Abakumov, MA1
Saltykova, IV1
Akhmirov, RT1
Garanina, AS1
Polshakov, VI1
Saveliev, OY1
Ivanenkov, YA1
Aladinskaya, AV1
Finko, AV1
Yamansarov, EU1
Krasnovskaya, OO1
Erofeev, AS1
Gorelkin, PV1
Dontsova, OA1
Beloglazkina, EK1
Zyk, NV1
Khazanova, ES1
Majouga, AG1
Zheng, YK1
Su, BJ1
Wang, YQ1
Wang, HS1
Liao, HB1
Liang, D1
Shataer, D1
Duan, XM1
Xin, XL1
Aisa, HA1
Allu, SR1
Ravotto, L1
Troxler, T1
Vinogradov, SA1
Cheruku, RR1
Tracy, EC1
Tabaczynski, W1
Missert, JR1
Baumann, H1
Pandey, RK1
Rohde, JM1
Karavadhi, S1
Pragani, R1
Fang, Y1
Zhang, W3
McIver, A1
Zheng, H1
Liu, Q1
Davis, MI1
Urban, DJ1
Lee, TD1
Cheff, DM1
Hollingshead, M1
Henderson, MJ1
Martinez, NJ1
Brimacombe, KR1
Yasgar, A1
Zhao, W1
Klumpp-Thomas, C1
Michael, S1
Covey, J1
Moore, WJ1
Stott, GM1
Li, Z3
Simeonov, A1
Jadhav, A1
Frye, S1
Hall, MD1
Shen, M1
Wang, X1
Patnaik, S1
Boxer, MB1
Zhang, H3
Cheng, C1
Huang, B1
Chen, R1
Huang, Y1
Chen, H1
Pei, W1
Katahara, S1
Sugiyama, Y1
Yamane, M1
Komiya, Y1
Sato, T1
Chida, N1
Antal, I1
Koneracka, M1
Kubovcikova, M1
Zavisova, V1
Jurikova, A1
Khmara, I1
Omastova, M1
Micusik, M1
Barathova, M1
Jelenska, L1
Kajanova, I1
Zatovicova, M1
Pastorekova, S1
Safa Shams Abyaneh, F1
Eslami Moghadam, M1
Hossaini Sadr, M1
Divsalar, A1
Sullivan, MR1
Vander Heiden, MG1
Archambault, V1
Normandin, K1
Amelio, I3
Melino, G3
Frezza, C1
Wan Makhtar, WR1
Browne, G1
Karountzos, A1
Stevens, C1
Alghamdi, Y1
Bottrill, AR1
Mistry, S1
Smith, E1
Bushel, M1
Pringle, JH1
Sayan, AE1
Tulchinsky, E1
Hanley, MJ4
Venkatakrishnan, K6
Bessudo, A2
Rasco, DW1
Sharma, S3
O'Neil, BH1
Liu, G3
Ke, A1
Patel, C1
Rowland Yeo, K1
Xia, C3
Zhang, X4
Esseltine, DL1
Nemunaitis, J3
Pusalkar, S2
Plesescu, M2
Chowdhury, S2
Shepard, DR1
Andreotti, G2
Koutros, S2
Hofmann, JN2
Sandler, DP3
Lubin, JH2
Lynch, CF2
Lerro, CC2
De Roos, AJ3
Parks, CG2
Alavanja, MC2
Silverman, DT2
Beane Freeman, LE2
Ward, EM1
Infante, PF1
Melnick, R1
Vainio, H2
Huff, J2
Park, JE1
Miller, Z1
Jun, Y1
Lee, W1
Kim, KB1
Davoren, MJ1
Schiestl, RH1
Hanley, M1
Wu, JT1
Sowers, ML1
Herring, J1
Tang, H1
Ou, Y1
Gu, W1
Zhang, K1
Pandey, B1
Patil, NG1
Bhosle, GS1
Ambade, AV1
Gupta, SS1
Sheppard, L1
Shaffer, RM1
Jin, P1
Sha, R1
Bian, Y1
Qian, J2
Ishimwe, N1
Hu, Y3
Yin, S1
Wen, LP1
Guo, T1
Qiu, Y1
Chen, X2
Song, J1
Yang, H4
Cherukula, K1
Uthaman, S1
Park, IK1
Fan, B1
Mellinghoff, IK1
Wen, PY1
Lowery, MA1
Goyal, L1
Tap, WD1
Pandya, SS1
Manyak, E1
Jiang, L1
Nimkar, T1
Gliser, C1
Prahl Judge, M1
Agresta, S1
Dai, D1
Samet, JM1
Morabia, A1
Arjó, G1
Portero, M1
Piñol, C1
Viñas, J1
Matias-Guiu, X1
Capell, T1
Bartholomaeus, A1
Parrott, W1
Christou, P1
Zhang, J1
Wu, P1
Ghosh, RD1
Banerjee, K1
Ganguly, A2
Chakraborty, P2
Sarkar, A1
Chatterjee, M2
Choudhuri, SK2
Aljahdali, M1
Locasale, JW2
Ham, DJ1
Murphy, KT1
Chee, A1
Lynch, GS1
Koopman, R1
Fan, AC1
O'Rourke, JJ1
Praharaj, DR1
Felsher, DW1
Li, Q1
Lambrechts, MJ1
Zhang, Q1
Liu, S3
Ge, D1
Yin, R1
Xi, M1
You, Z1
Tedeschi, PM2
Markert, EK1
Gounder, M1
Dvorzhinski, D1
Dolfi, SC1
Chan, LL1
Qiu, J1
DiPaola, RS1
Hirshfield, KM1
Boros, LG1
Bertino, JR2
Oltvai, ZN1
Vazquez, A3
Bowles, DW1
Diamond, JR1
Lam, ET1
Weekes, CD2
Astling, DP1
Anderson, RT1
Leong, S1
Gore, L1
Varella-Garcia, M1
Vogler, BW1
Keysar, SB1
Freas, E1
Aisner, DL1
Ren, C2
Tan, AC1
Wilhelm, F2
Maniar, M3
Eckhardt, SG2
Messersmith, WA3
Jimeno, A3
Kwiatkowska, M1
Paweł, J1
Bukowska, B2
Cutruzzolá, F1
Antonov, A2
Agostini, M2
van den Broek, NJ1
Mackay, GM1
Maddocks, OD1
Yagi, H1
Allegra, R1
Tunesi, S1
Cilia, R1
Pezzoli, G1
Goldwurm, S1
Liu, T1
Luo, S1
Tan, X1
Qi, Q1
Shi, C1
Infante, JR2
Weiss, GJ1
Jones, S1
Tibes, R1
Bauer, TM1
Bendell, JC1
Hinson, JM1
Von Hoff, DD1
Burris, HA1
Orlemans, EO1
Ramanathan, RK1
Lu, T1
Laughton, CA1
Bradshaw, TD1
Agalliu, I1
San Luciano, M1
Mirelman, A1
Giladi, N1
Waro, B1
Aasly, J1
Inzelberg, R1
Hassin-Baer, S1
Friedman, E1
Ruiz-Martinez, J1
Marti-Masso, JF1
Orr-Urtreger, A1
Bressman, S1
Saunders-Pullman, R1
Morello, M1
Minieri, M1
Mehrmohamadi, M1
Liu, X1
Shestov, AA1
Jiang, G1
Yin, F2
Duan, J1
Li, G1
Mitsiades, CS1
Smith, DC1
Kalebic, T1
Siu, LL1
Sullivan, D1
Vlahovic, G1
Kauh, JS1
Gao, F1
Berger, AJ1
Tirrell, S1
Di Bacco, A1
Berg, D1
Hui, AM3
Thompson, JA1
Guyton, KZ1
Loomis, D1
Grosse, Y1
El Ghissassi, F1
Benbrahim-Tallaa, L1
Guha, N1
Scoccianti, C1
Mattock, H1
Straif, K1
Huh, Y1
Hutmacher, MM1
Ottinger, S1
Jerbi, S1
Jolles, B1
Bouceba, T1
Jean-Jean, O1
Portier, CJ1
Armstrong, BK1
Baguley, BC1
Baur, X1
Belyaev, I1
Bellé, R1
Belpoggi, F1
Biggeri, A1
Bosland, MC1
Bruzzi, P1
Budnik, LT1
Bugge, MD1
Burns, K1
Calaf, GM1
Carpenter, DO1
Carpenter, HM1
López-Carrillo, L1
Clapp, R1
Cocco, P1
Consonni, D1
Comba, P1
Craft, E1
Dalvie, MA1
Davis, D1
Demers, PA1
DeWitt, J1
Forastiere, F1
Freedman, JH1
Fritschi, L1
Gaus, C1
Gohlke, JM1
Goldberg, M1
Greiser, E1
Hansen, J1
Hardell, L1
Hauptmann, M1
Huang, W1
James, MO1
Jameson, CW1
Kortenkamp, A1
Kopp-Schneider, A1
Kromhout, H1
Larramendy, ML1
Landrigan, PJ1
Lash, LH1
Leszczynski, D1
Magnani, C1
Mandrioli, D1
Martin, FL1
Merler, E1
Michelozzi, P1
Miligi, L1
Miller, AB1
Mirabelli, D1
Mirer, FE1
Naidoo, S1
Perry, MJ1
Petronio, MG1
Pirastu, R1
Portier, RJ1
Ramos, KS1
Robertson, LW1
Rodriguez, T1
Röösli, M1
Ross, MK1
Roy, D1
Saldiva, P1
Sass, J1
Savolainen, K1
Scheepers, PT1
Sergi, C1
Silbergeld, EK1
Smith, MT1
Stewart, BW1
Sutton, P1
Tateo, F1
Terracini, B1
Thielmann, HW1
Thomas, DB1
Vena, JE1
Vineis, P1
Weiderpass, E1
Weisenburger, DD1
Woodruff, TJ1
Yorifuji, T1
Yu, IJ1
Zambon, P1
Zeeb, H1
Zhou, SF1
Chang, ET1
Delzell, E1
Meiser, J1
Perez, R1
Norris, RE1
Qian, MG1
Falchook, G1
Labotka, R1
Pérez-Torres, I1
Zuniga-Munoz, AM1
Guarner-Lans, V1
Schulte-Wissermann, H1
Tarone, RE1
Gu, H1
Carroll, PA1
Du, J1
Zhu, J1
Neto, FC1
Eisenman, RN1
Raftery, D1
Bus, JS1
Laheru, D1
Rudek, MA1
Hidalgo, M1
Baker, SD1
Donehower, RC1
Niu, G1
Shi, J1
Wang, F1
Lao, VV1
Herring, JL1
Kim, CH1
Darwanto, A1
Soto, U1
Sowers, LC1
Ierano, C1
Giuliano, P1
D'Alterio, C1
Cioffi, M1
Mettivier, V1
Portella, L1
Napolitano, M1
Barbieri, A1
Arra, C1
Liguori, G1
Franco, R1
Palmieri, G1
Rozzo, C1
Pacelli, R1
Castello, G1
Scala, S1
Li, L1
Huang, X1
Huo, K1
Schöffski, P1
Reid, AH1
Protheroe, A1
Attard, G1
Hayward, N1
Vidal, L1
Spicer, J1
Shaw, HM1
Bone, EA2
Carter, J1
Hooftman, L2
Harris, A1
De Bono, JS1
Kupperman, E1
Lee, EC1
Cao, Y1
Bannerman, B1
Fitzgerald, M1
Berger, A1
Yang, Y1
Hales, P1
Bruzzese, F1
Liu, J1
Blank, J1
Garcia, K1
Tsu, C1
Dick, L1
Fleming, P1
Yu, L1
Rolfe, M1
Bolen, J1
Konkimalla, VB1
Efferth, T1
Voĭtenkov, VB1
Popovich, IG1
Zabezhinskiĭ, MA1
Iurova, MA1
Piskunova, TA1
Mikhaleva, II1
van Herpen, CM1
Eskens, FA1
de Jonge, M1
Desar, I1
Timmer-Bonte, JN1
Verweij, J1
Wickström, M1
Larsson, R1
Nygren, P1
Gullbo, J1
Rajan, A1
Kelly, RJ1
Trepel, JB1
Kim, YS1
Alarcon, SV1
Kummar, S1
Gutierrez, M1
Crandon, S1
Zein, WM1
Jain, L1
Mannargudi, B1
Figg, WD1
Houk, BE1
Shnaidman, M1
Brega, N1
Giaccone, G1
Dadwal, M1
Kang, CS1
Song, HA1
Sun, X1
Dai, A1
Baidoo, KE1
Brechbiel, MW1
Chong, HS1
Zhang, WC1
Shyh-Chang, N1
Umashankar, S1
Ma, S1
Soh, BS1
Sun, LL1
Tai, BC1
Nga, ME1
Bhakoo, KK1
Jayapal, SR1
Nichane, M1
Yu, Q1
Ahmed, DA1
Tan, C1
Sing, WP1
Tam, J1
Thirugananam, A1
Noghabi, MS1
Pang, YH1
Ang, HS1
Mitchell, W1
Robson, P1
Kaldis, P1
Soo, RA1
Swarup, S1
Lim, EH1
Lim, B1
Mullard, A1
Chatterjee, S1
Saha, P1
Adhikary, A1
Das, T1
Elliott, MA1
Ford, SJ1
Prasad, E1
Dick, LJ1
Farmer, H1
Hogg, PJ1
Halbert, GW1
Ma, WW1
Dy, GK1
Whitworth, A1
Adjei, AA1
Cho, JK1
Chun, C1
Kuh, HJ1
Song, SC1
Tomita, M1
Kami, K1
Jain, M1
Nilsson, R1
Madhusudhan, N1
Kitami, T1
Souza, AL1
Kafri, R1
Kirschner, MW1
Clish, CB1
Mootha, VK1
Mink, PJ1
Mandel, JS1
Sceurman, BK1
Lundin, JI1
Lan, R1
Lin, G1
Wang, J1
Gong, J1
Ding, YH1
Yang, Z1
Lu, F1
Lassila, R1
Fernández, A1
Roth, E1
Zellner, M1
Wessner, B1
Strasser, E1
Manhart, N1
Oehler, R1
Spittler, A1
LEPAGE, GA7
TYNER, EP2
HEIDELBERGER, C2
FORSSBERG, A2
KLEIN, G1
HEINZ, E3
BARCLAY, RK1
GARFINKEL, E1
KIT, S5
GRAHAM, OL2
GRUZDEVA, KN1
COLTER, JS1
KRITCHEVSKY, D1
BIRD, HH1
MCCANDLESS, RF1
MARIANI, HA1
WILLIAMS, AM1
BLECHER, M1
WHITE, A1
HARMON, DH1
KIRK, MR1
TOLBERT, BM1
FINLAYSON, JS1
DREYFUS, G1
SPRIGGS, AI1
LAJTHA, LG1
COLES, NW1
JOHNSTONE, RM2
QUASTEL, JH1
COSTAKEL, O1
KITULESCO, I1
VOICULET, N1
POPP, I1
HEMPLING, HG1
HARE, D1
ELLIS, DB1
SCHOLEFIELD, PG2
ROOF, BS1
RYSER, H1
AUB, JC1
BARTHOLOMEW, ME1
TUPPER, R1
WORMALL, A1
ZBARSKII, IB1
KARUZINA, NP1
GITTERMAN, CO3
DULANEY, EL3
KACZKA, EA3
HENDLIN, D2
WOODRUFF, HB2
HASCHEN, RJ1
SCHINDLER, R1
CHAUBE, S1
MURPHY, ML1
DE GREGORIO, P1
HARRIS, JJ1
TELLER, MN1
YAP-GUEVARA, E1
WOOLLEY, GW1
GRECO, AV1
CECCHI, F1
CARBONIN, PU1
SENSI, S1
GAMBASSI, G1
WU, C1
BAUER, JM1
WAGLE, SR1
ASHMORE, J1
LEVINE, AS1
MELONI, GA1
GENTY, N1
VENDRELY, R1
TERRANOVA, T2
FEO, F2
GRAVELA, E2
GABRIEL, L2
VANPILSUM, JF1
WARHOL, RM1
BECKMAN, D1
BOLINE, J1
CHRISTENSEN, HN1
BORENFREUND, E1
KRIM, M1
BENDICH, A1
RYAN, WL1
LORINCZ, AB1
CAMPBELL, GW1
PRADHAN, SN1
WEST, WL1
BENNETT, LL1
SMITHERS, D1
WARD, CT1
GORDON, JE1
WOOLFREY, BF1
DELOECKER, W2
ATCHLEY, WA1
BHAGAVAN, NV1
FOELSCH, E1
DREWS, J1
GRUNZE, H1
PAN, JC1
HO, S1
CHEN, CK1
BAI, YC1
HORKY, J1
PLACER, Z1
SHIGEURA, HT1
GORDON, CN1
MORSE, PA1
POTTER, VR1
DUNN, WL1
LOCKNER, D1
ERICSON, U1
HEVESY, G1
EDMONDS, MP1
GREENLEES, JL1
GREENLEES, J1
MINOWADA, J1
FOLKERS, K1
NORBERG, E1
GREENBERG, DM3
FARBER, E1
LOCKETT, MF1
EVANS, MM1
Mikawa, M1
Guo, L1
Liu, R1
Marik, J1
Takada, Y1
Lam, K1
Lau, D1
Blair, A1
Rusiecki, JA1
Hoppin, JA1
Svec, M1
Dosemeci, M1
Powis, G1
Wipf, P1
Lynch, SM1
Birmingham, A1
Kirkpatrick, DL1
von Guggenberg, E1
Dietrich, H1
Skvortsova, I1
Gabriel, M1
Virgolini, IJ1
Decristoforo, C1
Xiong, XB1
Mahmud, A1
Uludağ, H1
Lavasanifar, A1
Tannehill-Gregg, SH1
Sanderson, TP1
Minnema, D1
Voelker, R1
Ulland, B1
Cohen, SM1
Arnold, LL1
Schilling, BE1
Waites, CR1
Dominick, MA1
Teng, B1
Bai, Y1
Chang, Y1
Chen, S1
Avdievich, E1
Reiss, C1
Scherer, SJ1
Maier, SM1
Jin, B1
Hou, H1
Rosenwald, A1
Riedmiller, H1
Kucherlapati, R1
Cohen, PE1
Edelmann, W1
Kneitz, B1
Heckmann, D1
Meyer, A1
Laufer, B1
Zahn, G1
Stragies, R1
Kessler, H1
Lembach, K2
Charalampous, FC2
Fairchild, RG1
Bond, VP1
Stein, TP2
Ang, SD1
Schluter, MD1
Leskiw, MJ1
Nusbaum, M1
Levin, L1
Gevers, W1
Jardine, L1
De Guel, FJ1
Duncan, EJ1
Královec, J1
Krepelka, J1
Norton, JA1
Brennan, MF3
Kamada, S1
Maeda, M1
Tsuji, A1
Poster, DS1
Bruno, S1
Penta, J1
Neil, GL1
McGovren, JP1
Taylor, CR1
Shi, SR1
Chaiwun, B1
Young, L1
Imam, SA1
Cote, RJ1
Brugières, L1
Gardes, M1
Moutou, C1
Chompret, A1
Meresse, V1
Martin, A1
Poisson, N1
Flamant, F1
Bonaïti-Pellié, C1
Lemerle, J1
Hjelstuen, OK1
Maelandsmo, GM1
Tønnesen, HH1
Bremmer, PO1
Verbruggen, AM1
Renwick, SB1
Snell, K1
Baumann, U1
Ruediger, R1
Pham, HT1
Walter, G1
Van Aken, H1
Bode, C1
Darius, H1
Diehm, C1
Encke, A1
Gulba, DC1
Haas, S1
Hacke, W1
Puhl, W1
Quante, M1
Riess, H1
Scharf, R1
Schellong, S1
Schrör, T1
Schulte, KL1
Tebbe, U1
Tanaka, T1
Nakajima, T1
Nagata, K1
Suzuki, T1
Okano, Y1
Hamaguchi, M1
Nozawa, Y1
Jeevanandam, M2
Lowry, SF2
Horowitz, GD1
Rose, D1
Mihranian, MH1
Daly, J1
Discombe, G1
Lund, S1
Shimizu, T2
Bottici, R1
Ferrucci, A1
Taddeucci, E1
Harrison, HE1
Tiollais, P1
Björnesjö, KB2
Jarnulf, B1
Lausing, E1
Pisani, W1
Bonzanino, A1
Franco, G1

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1 Study of Oral IXAZOMIB (MLN9708) to Assess Relative Bioavailability, Food Effect, Drug-Drug Interaction With Ketoconazole, Clarithromycin or Rifampin; and Safety and Tolerability in Patients With Advanced Nonhematologic Malignancies or Lymphoma[NCT01454076]Phase 1112 participants (Actual)Interventional2011-11-10Completed
A Phase 1 Study of [ 14 C]-Ixazomib to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphoma[NCT01953783]Phase 17 participants (Actual)Interventional2014-03-19Completed
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation[NCT02073994]Phase 1170 participants (Anticipated)Interventional2014-03-01Active, not recruiting
Phase II Study of Paclitaxel and TAK-228 in Metastatic Urothelial Carcinoma (UC) and the Impact of PI3K-mTOR Pathway Genomic Alterations[NCT03745911]Phase 252 participants (Anticipated)Interventional2018-05-04Recruiting
Phase II Single-arm Study of ON 01910.Na by 2-hr Infusion in Patients With Recurring Platinum-resistant Ovarian Cancer[NCT00856791]Phase 21 participants (Actual)Interventional2009-03-31Completed
Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors[NCT01125891]Phase 139 participants (Actual)Interventional2009-01-31Completed
A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer[NCT01360853]Phase 3160 participants (Actual)Interventional2011-05-31Completed
A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)[NCT00854945]Phase 1/Phase 236 participants (Actual)Interventional2009-01-31Completed
A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Advanced Solid Tumors[NCT00861328]Phase 118 participants (Actual)Interventional2008-02-29Completed
A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Hepatoma and Other Advanced Solid Tumors[NCT00861783]Phase 116 participants (Actual)Interventional2008-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Ixazomib

(NCT01454076)
Timeframe: Arm 1:Days 1, 15 and Arm 5:Day 6 pre-dose and at multiple time points(up to 264 hrs)post-dose;Arm 2, 3:Days 1,15 pre-dose and at multiple time points(up to 216 hrs)post-dose;Arm 4:Day 8 pre-dose and at multiple time points(up to 168 hrs)post-dose

Interventionnanogram*hour per milliliter (ng*hr/mL)] (Geometric Mean)
Arm 1: Ixazomib 2.5 mg551.985
Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg1148.778
Arm 2: Ixazomib 4 mg Capsule A1284.079
Arm 2: Ixazomib 4 mg Capsule B1334.659
Arm 3: Ixazomib 4 mg Fasted1465.979
Arm 3: Ixazomib 4 mg Fed998.698
Arm 4: Ixazomib 4 mg + Rifampin 600 mg231.527
Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg613.112

Cmax: Maximum Observed Plasma Concentration for Ixazomib

(NCT01454076)
Timeframe: Arm 1:Days 1, 15 and Arm 5:Day 6 pre-dose and at multiple time points(up to 264 hours[hrs])post-dose;Arm 2, 3:Days 1,15 pre-dose and at multiple time points(up to 216 hrs)post-dose;Arm 4:Day 8 pre-dose and at multiple time points(up to 168 hrs)post-dose

Interventionnanogram per milliliter (ng/mL) (Geometric Mean)
Arm 1: Ixazomib 2.5 mg38.975
Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg39.250
Arm 2: Ixazomib 4 mg Capsule A61.866
Arm 2: Ixazomib 4 mg Capsule B71.949
Arm 3: Ixazomib 4 mg Fasted77.001
Arm 3: Ixazomib 4 mg Fed22.752
Arm 4: Ixazomib 4 mg + Rifampin 600 mg25.706
Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg37.245

Number of Participants With Clinically Significant Vital Sign Abnormalities

(NCT01454076)
Timeframe: Cycle 1 Day 1 up to 30 days after last dose of study drug (Arm 1 and 5: Cycle 19 Day 45; Arm 2: Cycle 7 Day 45; Arm 3: Cycle 22 Day 45; Arm 4: Cycle 25 Day 45

Interventionparticipants (Number)
Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg0
Arm 2: Ixazomib 4 mg Capsule A or B0
Arm 3: Ixazomib 4 mg Fasted or Fed0
Arm 4: Ixazomib 4 mg + Rifampin 600 mg0
Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg0

Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib

(NCT01454076)
Timeframe: Arm 1:Days 1, 15 and Arm 5:Day 6 pre-dose and at multiple time points(up to 264 hrs)post-dose;Arm 2, 3:Days 1,15 pre-dose and at multiple time points(up to 216 hrs)post-dose;Arm 4:Day 8 pre-dose and at multiple time points(up to 168 hrs)post-dose

Interventionhours (Median)
Arm 1: Ixazomib 2.5 mg1.090
Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg1.500
Arm 2: Ixazomib 4 mg Capsule A1.290
Arm 2: Ixazomib 4 mg Capsule B1.250
Arm 3: Ixazomib 4 mg Fasted1.020
Arm 3: Ixazomib 4 mg Fed4.000
Arm 4: Ixazomib 4 mg + Rifampin 600 mg1.450
Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg1

Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

(NCT01454076)
Timeframe: Cycle 1 Day 1 up to 30 days after last dose of study drug (Arm 1 and 5: Cycle 19 Day 45; Arm 2: Cycle 7 Day 45; Arm 3: Cycle 22 Day 45; Arm 4: Cycle 25 Day 45)

,,,,
Interventionparticipants (Number)
TEAEsSAEs
Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg2912
Arm 2: Ixazomib 4 mg Capsule A or B205
Arm 3: Ixazomib 4 mg Fasted or Fed2412
Arm 4: Ixazomib 4 mg + Rifampin 600 mg183
Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg2110

Number of Participants With Clinically Significant TEAEs Related to Laboratory Abnormalities

(NCT01454076)
Timeframe: Cycle 1 Day 1 up to 30 days after last dose of study drug (Arm 1 and 5: Cycle 19 Day 45; Arm 2: Cycle 7 Day 45; Arm 3: Cycle 22 Day 45; Arm 4: Cycle 25 Day 45

,,,,
Interventionparticipants (Number)
Blood and lymphatic system disordersInvestigationsMetabolism and nutrition disorders
Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg111022
Arm 2: Ixazomib 4 mg Capsule A or B7512
Arm 3: Ixazomib 4 mg Fasted or Fed91113
Arm 4: Ixazomib 4 mg + Rifampin 600 mg246
Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg156

Percentage of Participants With Best Overall Response

Best overall response for a participant is best observed post-baseline disease response as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1: Complete response (CR) was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than (<) 10 millimeter [mm]). No new lesions. Partial response (PR) was defined as greater than or equal to (>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease (SD) was defined as not qualifying for CR, PR, Progressive Disease (PD). An increase of >=20% from the nadir (or baseline, if it represents the point at which the sum of target disease was lowest) represents PD. (NCT01454076)
Timeframe: Baseline up to end of treatment (approximately 1.9 years)

,,,,
Interventionpercentage of participants (Number)
CRPRSDPD
Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg006338
Arm 2: Ixazomib 4 mg Capsule A or B005050
Arm 3: Ixazomib 4 mg Fasted or Fed063559
Arm 4: Ixazomib 4 mg + Rifampin 600 mg005347
Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg015347

Number of Participants With TEAEs Related to Vital Signs

Vital signs included oral body temperature, heart rate, and blood pressure. (NCT01953783)
Timeframe: Baseline up to Cycle 5 Day 25

Interventionparticipants (Number)
Ixazomib0

Part A: AUC(0-312): Area Under the Plasma Concentration-time Curve From Time 0 to 312 Hrs Post-dose for Ixazomib

AUC(0-312) is a measure of the area under the plasma concentration time-curve from time zero to 312 hrs post-dose for ixazomib. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to 312 hrs) post-dose

Interventionnanogram*hour per milliliter (ng*hr/mL) (Geometric Mean)
Ixazomib1181

Part A: AUC(0-816): Area Under the Plasma Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA

AUC(0-816) is a measure of the area under the plasma concentration time-curve from time zero to 816 hrs post-dose for TRA. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose

Interventionnanogram-equivalent*hour per milliliter (Geometric Mean)
Ixazomib2981

Part A: AUC(0-816): Area Under the Whole Blood Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA

AUC(0-816) is a measure of the area under the whole blood concentration time-curve from time zero to 816 hrs post-dose for TRA. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose

Interventionnanogram-equivalent* hour per milliliter (Geometric Mean)
Ixazomib29200

Part A: Cmax: Maximum Observed Plasma Concentration for Ixazomib

Maximum observed plasma concentration (Cmax) is the peak plasma concentration of ixazomib, obtained directly from the plasma concentration-time curve. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose

Interventionnanogram per milliliter (ng/mL) (Geometric Mean)
Ixazomib89.06

Part A: Cmax: Maximum Observed Plasma Concentration of TRA

Maximum observed plasma concentration (Cmax) of TRA is the peak plasma concentration of TRA, obtained directly from the plasma TRA concentration-time curve. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose

Interventionnanogram-equivalent per milliliter (Geometric Mean)
Ixazomib78.80

Part A: Cmax: Maximum Observed Whole Blood Concentration of TRA

Maximum observed whole blood concentration (Cmax) of a TRA is the peak whole blood concentration of TRA, obtained directly from the whole blood TRA concentration-time curve. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose

Interventionnanogram-equivalent per milliliter (Geometric Mean)
Ixazomib181.6

Part A: Cumulative Percentage of Ixazomib Dose Recovered in the Urine

Percentage of the ixazomib dose excreted unchanged in the urine from 0 to 168 hrs post-dose. (NCT01953783)
Timeframe: Day 1 of Part A from 0 to pre-dose and at multiple timepoints (up to 168 hrs) post-dose

Interventionpercentage of dose (Mean)
Ixazomib3.226

Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Feces

Percentage of the TRA dose excreted in feces from Day 1 to Day 35 of Part A (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose

Interventionpercentage of dose (Mean)
Ixazomib21.80

Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Urine

Percentage of the TRA dose excreted in urine from Day 1 to Day 35 of Part A. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose

Interventionpercentage of dose (Mean)
Ixazomib62.06

Part A: Renal Clearance of Ixazomib

Renal clearance is the volume of plasma from which ixazomib is completely removed by the kidney in a given amount of time, calculated as the amount of ixazomib excreted in the urine divided by the area under the plasma ixazomib concentration-time curve. (NCT01953783)
Timeframe: Day 1 pre-dose and at multiple timepoints (up to Day 14) post-dose

Interventionliter per hour (L/hr) (Geometric Mean)
Ixazomib0.1191

Part A: Tmax: Time to Reach the Cmax for TRA

Time to reach the maximum observed plasma concentration (Cmax) for TRA, equal to time (hours) to Cmax for TRA after administration, obtained directly from the plasma TRA concentration-time curve. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose

Interventionhr (Median)
Ixazomib0.5000

Part A: Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Ixazomib

Time to reach the maximum observed plasma concentration (Cmax), equal to time (hours) to Cmax of ixazomib after administration, obtained directly from the plasma concentration-time curve. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose

Interventionhour (hr) (Median)
Ixazomib0.5000

Part A: Tmax: Time to Reach the Maximum Observed Whole Blood Concentration (Cmax) for TRA

Time to reach the maximum observed whole blood concentration (Cmax) for TRA, equal to time (hours) to Cmax for TRA after administration, obtained directly from the whole blood TRA concentration-time curve. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose

Interventionhr (Median)
Ixazomib0.6000

Ixazomib and Metabolites as Percent of Total Dose Administered in Feces

"The 35-day post-dose data is extrapolated from the average of four participant data from 0-168-hr pooled feces. The data is therefore reported as percentage of dose with measure type as number and measure dispersion as NA." (NCT01953783)
Timeframe: Day 1 pre-dose and at multiple time points (up to Day 35) post-dose

Interventionpercentage of dose (Number)
FH6, ixazomibFH1FH2FH3, ML00701258FH4, ML00701201FH5FH7, ML00752034FH8FH9
Ixazomib13.80.9000.1110.6200.9011.141.580.5020.112

Ixazomib and Metabolites as Percent of Total Dose Administered in Urine

"The 35-day post-dose data is extrapolated from the average of four participant data from 0-168-hr pooled urine. The data is therefore reported as percentage of dose with measure type as number and measure dispersion as NA." (NCT01953783)
Timeframe: Day 1 pre-dose and at multiple time points (up to Day 35) post-dose

Interventionpercentage of dose (Number)
U9, ixazomibU1U2U3U4U5, ML00701258U6, ML00701201U7U8U10, ML00751996U11, ML00749506U12, ML00752034U13
Ixazomib1.300.3910.9261.611.332.7230.22.750.6955.931.280.0690.974

Ixazomib and Metabolites as Percent of Total Radioactivity in Plasma

"The plasma samples were pooled for participants over 816 hrs post-dose, and data was analysed using the Hamilton method time-proportional pooling, and therefore the data is reported as percent of total radioactivity in plasma with measure type as number and measure dispersion as Not applicable, NA." (NCT01953783)
Timeframe: Day 1 pre-dose and at multiple time points (up to 816 hrs) post-dose

Interventionpercent of total radioactivity in plasma (Number)
P4, ixazomibP2, ML00701258P3, ML00701201P6, ML00749506P7, ML00752034
Ixazomib54.27.9118.910.63.20

Number of Participants Reporting One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

(NCT01953783)
Timeframe: Baseline up to Cycle 5 Day 45

Interventionparticipants (Number)
TEAEsSAEs
Ixazomib71

Number of Participants With TEAEs Related to Investigations System Organ Class for Laboratory Values

(NCT01953783)
Timeframe: Baseline up to Cycle 5 Day 45

Interventionparticipants (Number)
Blood bilirubin increasedPlatelet count decreasedLymphocyte count decreased
Ixazomib111

Number of Adverse Events

The number of adverse events and their severity rating will be classified according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, version 3.0. (NCT00856791)
Timeframe: 6 months

InterventionAdverse event (Number)
ON 01910.Na9

Progression Free Survival

Progression-free survival, defined as the number of days from the first day of study drug dosing to the day of documented disease progression or death, as assessed using RECIST (Response Evaluation Criteria in Solid Tumors) guidelines according to Therasse P, Arbuck SF, Eisenhauer EA, et al. (2000) J Natl Cancer Inst. 92:205-216. Progressive disease is defined as at least a 20% increase in the sum of the longest diameter (LD)of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00856791)
Timeframe: 6 months

Interventionday (Number)
ON 01910.Na54

Reviews

41 reviews available for glycine and Neoplasms

ArticleYear
Glycinergic Signaling in Macrophages and Its Application in Macrophage-Associated Diseases.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Animals; Colitis; Glycine; Humans; Macrophages; Metabolic Diseases; MicroRNAs; Neoplasms; Reperfusio

2021
Phosphatases of regenerating liver are key regulators of metabolism in cancer cells - role of Serine/Glycine metabolism.
    Current opinion in clinical nutrition and metabolic care, 2022, 01-01, Volume: 25, Issue:1

    Topics: Glycine; Humans; Liver; Neoplasms; Protein Tyrosine Phosphatases; Serine

2022
Pleiotropic Outcomes of Glyphosate Exposure: From Organ Damage to Effects on Inflammation, Cancer, Reproduction and Development.
    International journal of molecular sciences, 2021, Nov-22, Volume: 22, Issue:22

    Topics: DNA Damage; Europe; Gene Expression Regulation; Glycine; Glyphosate; Herbicides; Humans; Inflammatio

2021
Clinical development of IDH1 inhibitors for cancer therapy.
    Cancer treatment reviews, 2022, Volume: 103

    Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Clinical Trials as Topic; Enzyme Inhibitor

2022
Current status of cancer starvation therapy.
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2022, Apr-25, Volume: 51, Issue:2

    Topics: Amino Acids; Angiogenesis Inhibitors; Glycine; Humans; Integrins; Neoplasms; Serine

2022
Integrin Alpha v Beta 6 (αvβ6) and Its Implications in Cancer Treatment.
    International journal of molecular sciences, 2022, Oct-15, Volume: 23, Issue:20

    Topics: Antigens, Neoplasm; Arginine; Aspartic Acid; Glycine; Humans; Integrin alphaV; Integrins; Neoplasms;

2022
Target enzymes in serine-glycine-one-carbon metabolic pathway for cancer therapy.
    International journal of cancer, 2023, 06-15, Volume: 152, Issue:12

    Topics: Carbon; Carcinogenesis; Glycine; Humans; Metabolic Networks and Pathways; Neoplasms; Serine

2023
New opportunities for RGD-engineered metal nanoparticles in cancer.
    Molecular cancer, 2023, 05-25, Volume: 22, Issue:1

    Topics: Amino Acid Sequence; Glycine; Humans; Metal Nanoparticles; Neoplasms; Oligopeptides

2023
The complexity of the serine glycine one-carbon pathway in cancer.
    The Journal of cell biology, 2020, 01-06, Volume: 219, Issue:1

    Topics: Animals; Carbon; Glycine; Humans; Metabolic Networks and Pathways; Neoplasms; Serine

2020
Accounting for Multiple Comparisons in Statistical Analysis of the Extensive Bioassay Data on Glyphosate.
    Toxicological sciences : an official journal of the Society of Toxicology, 2020, 06-01, Volume: 175, Issue:2

    Topics: Animals; Animals, Laboratory; Biological Assay; Carcinogenicity Tests; Data Interpretation, Statisti

2020
Reprogramming of serine, glycine and one-carbon metabolism in cancer.
    Biochimica et biophysica acta. Molecular basis of disease, 2020, 10-01, Volume: 1866, Issue:10

    Topics: Animals; Carbon; Cellular Reprogramming; Glycine; Humans; Metabolic Networks and Pathways; Methionin

2020
N-Myristoyltransferase as a Glycine and Lysine Myristoyltransferase in Cancer, Immunity, and Infections.
    ACS chemical biology, 2020, 07-17, Volume: 15, Issue:7

    Topics: Acyltransferases; Animals; Communicable Diseases; Enzyme Inhibitors; Glycine; Humans; Immunity, Inna

2020
Environmental Pollution, Oxidative Stress and Thioretinaco Ozonide: Effects of Glyphosate, Fluoride and Electromagnetic Fields on Mitochondrial Dysfunction in Carcinogenesis, Atherogenesis and Aging.
    Annals of clinical and laboratory science, 2020, Volume: 50, Issue:3

    Topics: Aging; Animals; Atherosclerosis; Carcinogenesis; Electromagnetic Fields; Environmental Pollution; Fl

2020
Cancer Cell Metabolites: Updates on Current Tracing Methods.
    Chembiochem : a European journal of chemical biology, 2020, 12-11, Volume: 21, Issue:24

    Topics: Amino Acids; Citric Acid; Glucose; Glycine; Humans; Isotope Labeling; Lactic Acid; Neoplasms; Succin

2020
The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.
    Anti-cancer agents in medicinal chemistry, 2021, Volume: 21, Issue:1

    Topics: Acetylation; Boron Compounds; Bortezomib; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis

2021
Serine, glycine and one‑carbon metabolism in cancer (Review).
    International journal of oncology, 2021, Volume: 58, Issue:2

    Topics: Animals; Antineoplastic Agents; Carbon; Carcinogenesis; Disease Models, Animal; Glycine; Humans; Met

2021
The ins and outs of serine and glycine metabolism in cancer.
    Nature metabolism, 2021, Volume: 3, Issue:2

    Topics: Animals; Glycine; Humans; Neoplasms; Serine

2021
Next-generation proteasome inhibitors for cancer therapy.
    Translational research : the journal of laboratory and clinical medicine, 2018, Volume: 198

    Topics: Antineoplastic Agents; Boron Compounds; Bortezomib; Drug Resistance, Neoplasm; Glycine; Humans; Neop

2018
Glyphosate-based herbicides and cancer risk: a post-IARC decision review of potential mechanisms, policy and avenues of research.
    Carcinogenesis, 2018, 10-08, Volume: 39, Issue:10

    Topics: Animals; Carcinogens; Environmental Exposure; Glycine; Glyphosate; Herbicides; Humans; Microbiota; M

2018
Clinical and marketed proteasome inhibitors for cancer treatment.
    Current medicinal chemistry, 2013, Volume: 20, Issue:20

    Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Pro

2013
Serine, glycine and one-carbon units: cancer metabolism in full circle.
    Nature reviews. Cancer, 2013, Volume: 13, Issue:8

    Topics: Epigenesis, Genetic; Glycine; Humans; Methylation; Neoplasms; Oxidation-Reduction; Serine

2013
Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.
    Expert opinion on investigational drugs, 2013, Volume: 22, Issue:11

    Topics: Antineoplastic Agents; Biomarkers; Glycine; Humans; Myelodysplastic Syndromes; Nanotechnology; Neopl

2013
[Glyphosate and its formulations--toxicity, occupational and environmental exposure].
    Medycyna pracy, 2013, Volume: 64, Issue:5

    Topics: Agriculture; Animals; Cholinesterase Inhibitors; Environmental Exposure; Glycine; Glyphosate; Herbic

2013
Serine and glycine metabolism in cancer.
    Trends in biochemical sciences, 2014, Volume: 39, Issue:4

    Topics: Cell Proliferation; Glycine; Humans; Metabolic Networks and Pathways; Neoplasms; Serine

2014
[Proteasome inhibitor].
    Nihon rinsho. Japanese journal of clinical medicine, 2014, Volume: 72, Issue:6

    Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Molecular Targeted Therapy; Neoplasms;

2014
Systematic review and meta-analysis of glyphosate exposure and risk of lymphohematopoietic cancers.
    Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes, 2016, Volume: 51, Issue:6

    Topics: Glycine; Glyphosate; Herbicides; Hodgkin Disease; Humans; Leukemia; Multiple Myeloma; Neoplasms; Ris

2016
Give it or take it: the flux of one-carbon in cancer cells.
    The FEBS journal, 2016, Volume: 283, Issue:20

    Topics: Animals; Carbon; Carbon Cycle; Cell Compartmentation; Cytosol; Embryonic Development; Glycine; Human

2016
Beneficial Effects of the Amino Acid Glycine.
    Mini reviews in medicinal chemistry, 2017, Volume: 17, Issue:1

    Topics: Animals; Antioxidants; Diabetes Mellitus, Type 2; Glycine; Humans; Insulin Resistance; Kidney; Liver

2017
IGFBP3 polymorphisms and risk of cancer: a meta-analysis.
    Molecular biology reports, 2010, Volume: 37, Issue:1

    Topics: Alanine; Alleles; Amino Acid Substitution; Case-Control Studies; Confidence Intervals; Genetic Predi

2010
Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
    The oncologist, 2009, Volume: 14, Issue:6

    Topics: Aniline Compounds; Animals; Cell Cycle Proteins; Clinical Trials as Topic; Cyclic N-Oxides; Drug Eva

2009
Aminopeptidase N (CD13) as a target for cancer chemotherapy.
    Cancer science, 2011, Volume: 102, Issue:3

    Topics: CD13 Antigens; Cell Proliferation; Clinical Trials as Topic; Glycine; Humans; Hydroxamic Acids; Leuc

2011
Epidemiologic studies of glyphosate and cancer: a review.
    Regulatory toxicology and pharmacology : RTP, 2012, Volume: 63, Issue:3

    Topics: Case-Control Studies; Cohort Studies; Glycine; Glyphosate; Herbicides; Humans; Neoplasms

2012
[Thrombosis in spite of warfarin--what should be done?].
    Duodecim; laaketieteellinen aikakauskirja, 2001, Volume: 117, Issue:24

    Topics: Anticoagulants; Antiphospholipid Syndrome; Azetidines; Benzylamines; Blood Coagulation; Glycine; Hep

2001
Glycine--an inert amino acid comes alive.
    Nutrition (Burbank, Los Angeles County, Calif.), 2003, Volume: 19, Issue:9

    Topics: Adjuvants, Immunologic; Amino Acids; Cytoprotection; Fibrinolytic Agents; Glycine; Humans; Neoplasms

2003
[Glutathione: its biosynthesis, induction agents and concentrations in selected diseases].
    Medycyna pracy, 2004, Volume: 55, Issue:6

    Topics: Animals; Cysteine; Cystine; Glutamic Acid; Glutathione; Glycine; Humans; Male; Neoplasms

2004
New compounds for neutron capture therapy (NCT) and their significance.
    Strahlentherapie, 1984, Volume: 160, Issue:12

    Topics: Animals; Borohydrides; Boron Compounds; Combined Modality Therapy; Cricetinae; Deoxyuridine; Glycine

1984
[Synthetic immunostimulation and its use in antineoplasm therapy].
    Ceskoslovenska farmacie, 1982, Volume: 31, Issue:5

    Topics: Adjuvants, Immunologic; Amino Acids; Anti-Bacterial Agents; Aziridines; Glycine; Hormones; Humans; I

1982
Acivicin. An antitumor antibiotic.
    Cancer clinical trials, 1981,Fall, Volume: 4, Issue:3

    Topics: Animals; Antibiotics, Antineoplastic; Glycine; Humans; Isoxazoles; Neoplasms; Neoplasms, Experimenta

1981
Anticoagulation: the present and future.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2001, Volume: 7, Issue:3

    Topics: Administration, Oral; Amino Acid Chloromethyl Ketones; Anticoagulants; Arginine; Azetidines; Benzyla

2001
Oncogenous rickets: possible elaboration by a tumor of a humoral substance inhibiting tubular reabsorption of phosphate.
    Pediatrics, 1973, Volume: 52, Issue:3

    Topics: Calcitonin; Calcium; Child; Glycine; Growth Disorders; Humans; Kidney Tubules; Kidney Tubules, Proxi

1973
[Action of the adrenal cortex hormones on lymphiod tissue].
    Exposes annuels de biochimie medicale, 1967, Volume: 28

    Topics: Adrenal Cortex Hormones; Amino Acids; Animals; Carbon Isotopes; Cell Membrane; Enzyme Induction; Glu

1967

Trials

19 trials available for glycine and Neoplasms

ArticleYear
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
    Investigational new drugs, 2022, Volume: 40, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2022
Open-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies.
    American journal of hematology, 2023, Volume: 98, Issue:5

    Topics: Anemia; Antineoplastic Agents; Erythropoietin; Glycine; Hematinics; Hemoglobins; Humans; Isoquinolin

2023
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
    Scientific reports, 2020, 02-20, Volume: 10, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Boron Compounds; Glycine; Humans; Indazoles; Kaplan-Meier Esti

2020
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Ana
    Journal of clinical pharmacology, 2018, Volume: 58, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boron Compounds; Clarit

2018
A phase I study to assess the mass balance, excretion, and pharmacokinetics of [
    Investigational new drugs, 2018, Volume: 36, Issue:3

    Topics: Administration, Oral; Aged; Boron Compounds; Carbon Radioisotopes; Feces; Female; Glycine; Humans; M

2018
Biotransformation of [
    Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:5

    Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Biotransformation; Boron Compounds; C

2018
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
    Investigational new drugs, 2020, Volume: 38, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relations

2020
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Mar-15, Volume: 20, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cell Cycle Proteins; Enzyme Inhibitors; Fe

2014
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:17

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Benzamides; Bio

2014
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
    Investigational new drugs, 2015, Volume: 33, Issue:3

    Topics: Activating Transcription Factor 3; Adult; Aged; Boron Compounds; Cohort Studies; Dose-Response Relat

2015
The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
    Journal of clinical pharmacology, 2016, Volume: 56, Issue:10

    Topics: Aged; Aged, 80 and over; Area Under Curve; Biological Availability; Boron Compounds; Cross-Over Stud

2016
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
    British journal of clinical pharmacology, 2016, Volume: 82, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Boron Compounds; Female; Glycine; Humans; Live

2016
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F

2008
A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Aug-01, Volume: 15, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Aminopeptidases; Dose-Response Relationship, Drug; Enzyme Inhibitors

2009
A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.
    British journal of cancer, 2010, Oct-26, Volume: 103, Issue:9

    Topics: Adult; Aged; Aminopeptidases; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sc

2010
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Nov-01, Volume: 17, Issue:21

    Topics: Adult; Aged; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gly

2011
Pharmaceutical development of the novel arsenical based cancer therapeutic GSAO for Phase I clinical trial.
    International journal of pharmaceutics, 2012, Apr-15, Volume: 426, Issue:1-2

    Topics: Angiogenesis Inhibitors; Antioxidants; Arsenicals; Calorimetry, Differential Scanning; Chemistry, Ph

2012
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-01, Volume: 18, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ce

2012
[First results of the clinical use of injectable lysine acetylsalicylate].
    Minerva medica, 1972, Nov-21, Volume: 63, Issue:83

    Topics: Adult; Aged; Analgesics; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Drug Combinations

1972

Other Studies

173 other studies available for glycine and Neoplasms

ArticleYear
Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement.
    Current drug metabolism, 2021, Volume: 22, Issue:9

    Topics: Animals; Biomarkers, Pharmacological; Biomarkers, Tumor; Chromatography, Liquid; Drug Development; G

2021
The impact of physiological metabolite levels on serine uptake, synthesis and utilization in cancer cells.
    Nature communications, 2021, 10-26, Volume: 12, Issue:1

    Topics: Biosynthetic Pathways; Cell Line, Tumor; Cell Proliferation; Culture Media; Glycine; Humans; Hypoxan

2021
Platinum-based nanocomposites loaded with MTH1 inhibitor amplify oxidative damage for cancer therapy.
    Colloids and surfaces. B, Biointerfaces, 2022, Volume: 218

    Topics: Arginine; Aspartic Acid; Catalase; Cell Line, Tumor; Glycine; Humans; Hydrogen Peroxide; Liposomes;

2022
Exploratory Metabolomics Underscores the Folate Enzyme ALDH1L1 as a Regulator of Glycine and Methylation Reactions.
    Molecules (Basel, Switzerland), 2022, Dec-01, Volume: 27, Issue:23

    Topics: Aldehyde Dehydrogenase 1 Family; Folic Acid; Glycine; Humans; Metabolomics; Methylation; Neoplasms;

2022
Exploratory Metabolomics Underscores the Folate Enzyme ALDH1L1 as a Regulator of Glycine and Methylation Reactions.
    Molecules (Basel, Switzerland), 2022, Dec-01, Volume: 27, Issue:23

    Topics: Aldehyde Dehydrogenase 1 Family; Folic Acid; Glycine; Humans; Metabolomics; Methylation; Neoplasms;

2022
Exploratory Metabolomics Underscores the Folate Enzyme ALDH1L1 as a Regulator of Glycine and Methylation Reactions.
    Molecules (Basel, Switzerland), 2022, Dec-01, Volume: 27, Issue:23

    Topics: Aldehyde Dehydrogenase 1 Family; Folic Acid; Glycine; Humans; Metabolomics; Methylation; Neoplasms;

2022
Exploratory Metabolomics Underscores the Folate Enzyme ALDH1L1 as a Regulator of Glycine and Methylation Reactions.
    Molecules (Basel, Switzerland), 2022, Dec-01, Volume: 27, Issue:23

    Topics: Aldehyde Dehydrogenase 1 Family; Folic Acid; Glycine; Humans; Metabolomics; Methylation; Neoplasms;

2022
Identification and Biological Evaluation of a Water-Soluble Fullerene Nanomaterial as BTK Kinase Inhibitor.
    International journal of nanomedicine, 2023, Volume: 18

    Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Caspases; Fullerenes; Glycine; Hematolog

2023
Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS
    Journal of medicinal chemistry, 2023, 07-13, Volume: 66, Issue:13

    Topics: Animals; Antineoplastic Agents; Drug Design; Glycine; Humans; Lung Neoplasms; Mutation; Neoplasms; P

2023
Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation.
    The Journal of clinical investigation, 2019, 08-08, Volume: 129, Issue:11

    Topics: Animals; Cell Line, Tumor; Cellular Reprogramming; Energy Metabolism; Glycine; Humans; Mice; Mutatio

2019
Nutraceutical targeting of TLR4 signaling has potential for prevention of cancer cachexia.
    Medical hypotheses, 2019, Volume: 132

    Topics: 3-Hydroxybutyric Acid; Adipocytes; Biotin; Cachexia; Carnitine; Catechin; Coumaric Acids; Dietary Su

2019
Enlargement of a Modular System-Synthesis and Characterization of an
    Molecules (Basel, Switzerland), 2019, Sep-10, Volume: 24, Issue:18

    Topics: Boron; Boron Compounds; Boron Neutron Capture Therapy; Carboxylic Acids; Drug Delivery Systems; Este

2019
Difficulties in establishing a causal link between chemical exposures and cancer cannot be overcome by court assessments.
    Human & experimental toxicology, 2020, Volume: 39, Issue:8

    Topics: Environmental Exposure; Environmental Pollutants; Glycine; Glyphosate; Humans; Jurisprudence; Neopla

2020
Acetonitrilated Unsymmetric BODIPYs having glycine fluorescence responsive quenching: Design, synthesis and spectroscopic properties.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2020, Jun-05, Volume: 233

    Topics: Antineoplastic Agents; Boron Compounds; Cell Line, Tumor; Fluorescent Dyes; Glycine; Humans; Microsc

2020
Glyphosate and cancer: the importance of the whole picture.
    Pest management science, 2020, Volume: 76, Issue:9

    Topics: Agrochemicals; Glycine; Glyphosate; Humans; Neoplasms; Pest Control

2020
Questioning Existing Cancer Hazard Evaluation Standards in the Name of Statistics.
    Toxicological sciences : an official journal of the Society of Toxicology, 2020, 10-01, Volume: 177, Issue:2

    Topics: Biological Assay; Glycine; Glyphosate; Humans; Neoplasms; Reference Standards

2020
Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent.
    Molecular cell, 2020, 07-02, Volume: 79, Issue:1

    Topics: Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Crystallography, X-Ray; Drug Contaminati

2020
Serine restriction alters sphingolipid diversity to constrain tumour growth.
    Nature, 2020, Volume: 586, Issue:7831

    Topics: Alanine; Animals; Cell Adhesion; Cell Division; Diet; Female; Glycine; HCT116 Cells; Humans; Membran

2020
Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank.
    British journal of cancer, 2020, Volume: 123, Issue:9

    Topics: Adult; Aged; Amino Acid Substitution; Biological Specimen Banks; Case-Control Studies; Female; Gene

2020
Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy.
    Nature communications, 2021, 01-14, Volume: 12, Issue:1

    Topics: Activating Transcription Factor 4; Animals; Cell Line, Tumor; Cell Proliferation; Female; Glycine; H

2021
Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals.
    PLoS genetics, 2021, Volume: 17, Issue:2

    Topics: Alleles; Carcinogenesis; Cell Line, Tumor; Gene Frequency; Genotype; Glycine; HLA Antigens; Humans;

2021
    Journal of applied social psychology, 2021, Volume: 51, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Animals; Anti-Bacterial Agents; Anti-

2021
Targeting of carbonic anhydrase IX-positive cancer cells by glycine-coated superparamagnetic nanoparticles.
    Colloids and surfaces. B, Biointerfaces, 2021, Volume: 205

    Topics: Carbonic Anhydrase IX; Glycine; Humans; Magnetic Iron Oxide Nanoparticles; Nanoparticles; Neoplasms

2021
Effect of lipophilicity of amylamine and amylglycine ligands on biological activity of new anticancer cisplatin analog.
    Journal of biomolecular structure & dynamics, 2018, Volume: 36, Issue:4

    Topics: Amines; Antineoplastic Agents; Circular Dichroism; Cisplatin; DNA; Glycine; HCT116 Cells; Humans; Li

2018
When cancer needs what's non-essential.
    Nature cell biology, 2017, Volume: 19, Issue:5

    Topics: Animals; Cell Proliferation; Diet, Protein-Restricted; Energy Metabolism; Glycine; Humans; Mice; Neo

2017
Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators.
    Cell cycle (Georgetown, Tex.), 2017, Jun-18, Volume: 16, Issue:12

    Topics: Alkylation; Antineoplastic Agents; Benzoates; Benzoquinones; Cell Cycle Proteins; Glycine; Humans; M

2017
Exploiting tumour addiction with a serine and glycine-free diet.
    Cell death and differentiation, 2017, Volume: 24, Issue:8

    Topics: Diet; Glycine; Humans; Neoplasms; Serine

2017
Short stretches of rare codons regulate translation of the transcription factor ZEB2 in cancer cells.
    Oncogene, 2017, 11-23, Volume: 36, Issue:47

    Topics: Amino Acid Motifs; Cell Line, Tumor; Codon; Epithelial-Mesenchymal Transition; Glycine; Humans; Leuc

2017
Glyphosate Use and Cancer Incidence in the Agricultural Health Study.
    Journal of the National Cancer Institute, 2018, 05-01, Volume: 110, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Agricultural Workers' Diseases; Agriculture; Cohort Studies; Farmers

2018
Glyphosate Use and Cancer Incidence in the Agricultural Health Study: An Epidemiologic Perspective.
    Journal of the National Cancer Institute, 2018, 05-01, Volume: 110, Issue:5

    Topics: Agriculture; Glycine; Glyphosate; Humans; Incidence; Neoplasms

2018
Commentary: IARC Monographs Program and public health under siege by corporate interests.
    American journal of industrial medicine, 2018, Volume: 61, Issue:4

    Topics: Carcinogens; Conflict of Interest; Glycine; Glyphosate; Herbicides; Humans; International Agencies;

2018
Ready reckoning.
    Nature plants, 2018, Volume: 4, Issue:9

    Topics: California; Chemical Industry; Glycine; Glyphosate; Herbicides; Humans; Liability, Legal; Neoplasms

2018
Analysis of glucose-derived amino acids involved in one-carbon and cancer metabolism by stable-isotope tracing gas chromatography mass spectrometry.
    Analytical biochemistry, 2019, 02-01, Volume: 566

    Topics: Amino Acids; Carbon; Carbon Isotopes; Cell Line, Tumor; Gas Chromatography-Mass Spectrometry; Glucos

2019
Amphiphilic Glycopolypeptide Star Copolymer-Based Cross-Linked Nanocarriers for Targeted and Dual-Stimuli-Responsive Drug Delivery.
    Bioconjugate chemistry, 2019, 03-20, Volume: 30, Issue:3

    Topics: Alkynes; Antibiotics, Antineoplastic; Cross-Linking Reagents; Delayed-Action Preparations; Doxorubic

2019
Re: Glyphosate Use and Cancer Incidence in the Agricultural Health Study.
    Journal of the National Cancer Institute, 2019, 02-01, Volume: 111, Issue:2

    Topics: Agriculture; Glycine; Glyphosate; Humans; Incidence; Neoplasms

2019
Response to Sheppard and Shaffer.
    Journal of the National Cancer Institute, 2019, 02-01, Volume: 111, Issue:2

    Topics: Glycine; Glyphosate; Humans; Incidence; Neoplasms

2019
Blood Circulation-Prolonging Peptides for Engineered Nanoparticles Identified via Phage Display.
    Nano letters, 2019, 03-13, Volume: 19, Issue:3

    Topics: Amino Acid Sequence; Arginine; Aspartic Acid; Bacteriophage M13; Biological Transport; Cell Surface

2019
A Highly Effective π-π Stacking Strategy To Modify Black Phosphorus with Aromatic Molecules for Cancer Theranostics.
    ACS applied materials & interfaces, 2019, Mar-13, Volume: 11, Issue:10

    Topics: Arginine; Aspartic Acid; Glycine; Humans; Nanocomposites; Neoplasms; Peptides; Phosphorus; Photother

2019
Design of an Amphiphilic Poly(aspartamide)-mediated Self-assembled Nanoconstruct for Long-Term Tumor Targeting and Bioimaging.
    Molecules (Basel, Switzerland), 2019, Mar-02, Volume: 24, Issue:5

    Topics: Amines; Animals; Cell Line, Tumor; Doxorubicin; Gene Expression Regulation, Neoplastic; Glycine; Hum

2019
Expert Review Under Attack: Glyphosate, Talc, and Cancer.
    American journal of public health, 2019, Volume: 109, Issue:7

    Topics: Asbestos; Glycine; Glyphosate; Humans; Neoplasms; Politics; Talc

2019
Fighting Independent Risk Assessment of Talc and Glyphosate: Whose Benefit Is It Anyway?
    American journal of public health, 2019, Volume: 109, Issue:7

    Topics: Glycine; Glyphosate; Humans; Neoplasms; Risk Assessment; Talc

2019
Plurality of opinion, scientific discourse and pseudoscience: an in depth analysis of the Séralini et al. study claiming that Roundup™ Ready corn or the herbicide Roundup™ cause cancer in rats.
    Transgenic research, 2013, Volume: 22, Issue:2

    Topics: Animals; Cultural Diversity; Drug Tolerance; Food, Genetically Modified; Glycine; Glyphosate; Herbic

2013
A novel manganese complex, Mn-(II) N-(2-hydroxy acetophenone) glycinate overcomes multidrug-resistance in cancer.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2013, Jul-16, Volume: 49, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Line, Tumor; Cell Survival; Cells

2013
Synthesis, characterization and equilibrium studies of some potential antimicrobial and antitumor complexes of Cu(II), Ni(II), Zn(II) and Cd(II) ions involving 2-aminomethylbenzimidazole and glycine.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2013, Volume: 112

    Topics: Anti-Infective Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Benzimidazoles; Cell L

2013
Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia.
    Clinical nutrition (Edinburgh, Scotland), 2014, Volume: 33, Issue:3

    Topics: Adipose Tissue; Animals; Body Mass Index; Cachexia; Cell Line, Tumor; Disease Models, Animal; Fatty

2014
Glyphosate and AMPA inhibit cancer cell growth through inhibiting intracellular glycine synthesis.
    Drug design, development and therapy, 2013, Volume: 7

    Topics: Apoptosis; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Epithelial

2013
Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells.
    Cell death & disease, 2013, Oct-24, Volume: 4

    Topics: Adenosine Triphosphate; Amino Acid Oxidoreductases; Animals; Carrier Proteins; Cell Line, Tumor; Emb

2013
Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells.
    Cell reports, 2014, May-22, Volume: 7, Issue:4

    Topics: Carbon; Cell Growth Processes; Glycine; HCT116 Cells; Humans; MCF-7 Cells; Metabolic Networks and Pa

2014
LRRK2-G2019S mutation is not associated with an increased cancer risk: a kin-cohort study.
    Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:10

    Topics: Case-Control Studies; Cohort Studies; Female; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine

2014
Synthesis and characterization of a glycine-modified heptamethine indocyanine dye for in vivo cancer-targeted near-infrared imaging.
    Drug design, development and therapy, 2014, Volume: 8

    Topics: Animals; Biocompatible Materials; Dose-Response Relationship, Drug; Fluorescent Dyes; Glycine; Hep G

2014
In vitro antitumor mechanism of (E)-N-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methanesulfonamide.
    Molecular pharmacology, 2015, Volume: 87, Issue:1

    Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation,

2015
Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
    JAMA neurology, 2015, Volume: 72, Issue:1

    Topics: Aged; Aged, 80 and over; Europe; Female; Genetic Association Studies; Genetic Predisposition to Dise

2015
Bioinformatics analysis of the serine and glycine pathway in cancer cells.
    Oncotarget, 2014, Nov-30, Volume: 5, Issue:22

    Topics: Animals; Computational Biology; Genomics; Glycine; Humans; Mice; Neoplasms; Serine; Survival Analysi

2014
Characterization of the usage of the serine metabolic network in human cancer.
    Cell reports, 2014, Nov-20, Volume: 9, Issue:4

    Topics: Carbon; Gene Expression Regulation, Neoplastic; Glutathione; Glycine; Humans; Metabolic Flux Analysi

2014
Synthesis and properties of novel water-soluble fullerene-glycine derivatives as new materials for cancer therapy.
    Journal of materials science. Materials in medicine, 2015, Volume: 26, Issue:1

    Topics: Biocompatible Materials; Carbon; Cell Line, Tumor; Drug Design; Flow Cytometry; Fullerenes; Glycine;

2015
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-01, Volume: 33, Issue:7

    Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials

2015
Carcinogenicity of tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate.
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Carcinogenesis; Diazinon; Glycine; Glyphosate; Humans; Malathion; Neoplasms; Parathion; Pesticides;

2015
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:3

    Topics: Animals; Boron Compounds; Clinical Trials, Phase I as Topic; Dogs; Electrocardiography; Ether-A-Go-G

2015
Studies on human eRF3-PABP interaction reveal the influence of eRF3a N-terminal glycin repeat on eRF3-PABP binding affinity and the lower affinity of eRF3a 12-GGC allele involved in cancer susceptibility.
    RNA biology, 2016, Volume: 13, Issue:3

    Topics: Alleles; Binding Sites; Genetic Predisposition to Disease; Genetic Variation; Glycine; Humans; Model

2016
Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA).
    Journal of epidemiology and community health, 2016, Volume: 70, Issue:8

    Topics: Carcinogens; Consumer Product Safety; European Union; Food Safety; Glycine; Glyphosate; Herbicides;

2016
[Is there a threat to ban the herbicide glyphosate?].
    Kinderkrankenschwester : Organ der Sektion Kinderkrankenpflege, 2016, Volume: 35, Issue:6

    Topics: Consumer Product Safety; Food Contamination; Germany; Glycine; Glyphosate; Hazard Analysis and Criti

2016
On the International Agency for Research on Cancer classification of glyphosate as a probable human carcinogen.
    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2018, Volume: 27, Issue:1

    Topics: Animals; Carcinogenicity Tests; Carcinogens; Glycine; Glyphosate; Humans; International Agencies; Mo

2018
Quantitative Method to Investigate the Balance between Metabolism and Proteome Biomass: Starting from Glycine.
    Angewandte Chemie (International ed. in English), 2016, 12-12, Volume: 55, Issue:50

    Topics: Amino Acids; Cell Line, Tumor; Cell Proliferation; Glycine; Humans; Metabolic Networks and Pathways;

2016
IARC use of oxidative stress as key mode of action characteristic for facilitating cancer classification: Glyphosate case example illustrating a lack of robustness in interpretative implementation.
    Regulatory toxicology and pharmacology : RTP, 2017, Volume: 86

    Topics: Animals; Carcinogens; Glycine; Glyphosate; Humans; International Agencies; Neoplasms; Oxidative Stre

2017
(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging.
    European journal of nuclear medicine and molecular imaging, 2009, Volume: 36, Issue:6

    Topics: Animals; Cell Line, Tumor; Dimerization; Female; Gallium Radioisotopes; Glycine; Humans; Integrin al

2009
Incorporation of 5-chlorocytosine into mammalian DNA results in heritable gene silencing and altered cytosine methylation patterns.
    Carcinogenesis, 2009, Volume: 30, Issue:5

    Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Cytosine; DNA; DNA Damage; DNA Replication; Gene Silenci

2009
A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration.
    Cell cycle (Georgetown, Tex.), 2009, Apr-15, Volume: 8, Issue:8

    Topics: Alanine; Amino Acid Sequence; Amino Acid Substitution; Animals; Cell Line, Tumor; Cell Movement; Cel

2009
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
    Cancer research, 2010, Mar-01, Volume: 70, Issue:5

    Topics: Animals; Boron Compounds; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Drug Screening

2010
Inhibition of epidermal growth factor receptor-overexpressing cancer cells by camptothecin, 20-(N,N-diethyl) glycinate.
    Biochemical pharmacology, 2010, Jul-01, Volume: 80, Issue:1

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Evaluation, Preclinical; Erb

2010
[Effect of delta-sleep inducing peptide preparation Deltaran on longevity, physiological functions, and carcinogenesis in mice].
    Advances in gerontology = Uspekhi gerontologii, 2009, Volume: 22, Issue:4

    Topics: Animals; Antioxidants; Biomarkers; Body Weight; Delta Sleep-Inducing Peptide; Drug Administration Sc

2009
Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates.
    Bioorganic & medicinal chemistry letters, 2011, Dec-15, Volume: 21, Issue:24

    Topics: Antibodies, Monoclonal, Humanized; Bismuth; Drug Evaluation, Preclinical; Drug Stability; Glycine; H

2011
Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis.
    Cell, 2012, Jan-20, Volume: 148, Issue:1-2

    Topics: Amino Acid Sequence; Antigens, CD; Carcinoma, Non-Small-Cell Lung; Cell Adhesion Molecules, Neuronal

2012
Next-generation proteasome blockers promise safer cancer therapy.
    Nature medicine, 2012, Jan-06, Volume: 18, Issue:1

    Topics: Antineoplastic Agents; Boron Compounds; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Dr

2012
Reprogramming of TAM toward proimmunogenic type through regulation of MAP kinases using a redox-active copper chelate.
    Journal of leukocyte biology, 2012, Volume: 91, Issue:4

    Topics: Animals; Cell Line, Tumor; Chelating Agents; Enzyme Activation; Female; Glycine; Interferon-gamma; I

2012
Injectable poly(organophosphazene)-camptothecin conjugate hydrogels: synthesis, characterization, and antitumor activities.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2012, Volume: 81, Issue:3

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Stability; D

2012
Cancer. Systems biology, metabolomics, and cancer metabolism.
    Science (New York, N.Y.), 2012, May-25, Volume: 336, Issue:6084

    Topics: Cell Proliferation; Glycine; Humans; Neoplasms

2012
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
    Science (New York, N.Y.), 2012, May-25, Volume: 336, Issue:6084

    Topics: Breast Neoplasms; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation,

2012
Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.
    Laboratory investigation; a journal of technical methods and pathology, 2012, Volume: 92, Issue:10

    Topics: Amides; Animals; Aurora Kinase A; Aurora Kinases; Benzimidazoles; Cell Cycle Proteins; Cell Division

2012
Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors.
    Cancer research, 2013, Jan-15, Volume: 73, Issue:2

    Topics: Biological Transport; Folic Acid; Folic Acid Antagonists; Glycine; Humans; Methotrexate; Mitochondri

2013
A wholly nutritional 'multifocal angiostatic therapy' for control of disseminated cancer.
    Medical hypotheses, 2003, Volume: 61, Issue:1

    Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Copper; Cyclic AMP; Diet; Diet, Vege

2003
Oncogenic mutations and packing defects in protein structure.
    Journal of biomolecular structure & dynamics, 2003, Volume: 21, Issue:1

    Topics: Alanine; Amino Acid Sequence; Amino Acid Substitution; Arginine; Binding Sites; Glycine; Hydrogen Bo

2003
In vitro incorporation of glycine-2-C14 into purines and proteins.
    Cancer research, 1953, Volume: 13, Issue:2

    Topics: Glycine; In Vitro Techniques; Neoplasms; Nucleic Acids; Proteins; Purines

1953
Intracellular distribution of radioactivity in nucleic acid nucleotides and proteins following simultaneous administration of P32 and glycine-2-C14.
    Cancer research, 1953, Volume: 13, Issue:2

    Topics: Cytoplasm; Glycine; Neoplasms; Nucleic Acids; Nucleotides; Phosphorus; Phosphorus Radioisotopes; Pro

1953
Studies on the effect of X-rays on the biochemistry and cellular composition of ascites tumors. II. Changes in the pattern of glycine-2-14C incorporation during the first two hours after irradiation in vivo.
    Experimental cell research, 1954, Volume: 7, Issue:2

    Topics: Animals; Ascites; Carcinoma, Ehrlich Tumor; Glycine; Neoplasms; X-Rays

1954
Kinetic studies on the influx of glycine-1-C14 into the Ehrlich mouse ascites carcinoma cell.
    The Journal of biological chemistry, 1954, Volume: 211, Issue:2

    Topics: Animals; Ascites; Fabaceae; Glycine; Kinetics; Mice; Neoplasms

1954
Glycine and adenine as precursors of nucleic acid purines in tumor-bearing mice.
    The Journal of biological chemistry, 1955, Volume: 212, Issue:1

    Topics: Adenine; Animals; Glycine; Mice; Neoplasms; Nucleic Acids; Purines

1955
The biosynthesis of free glycine and serine by tumors.
    Cancer research, 1955, Volume: 15, Issue:11

    Topics: Glycine; Humans; Neoplasms; Serine

1955
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
    Cancer research, 1956, Volume: 16, Issue:10 Part 1

    Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl

1956
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
    Cancer research, 1956, Volume: 16, Issue:10 Part 1

    Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl

1956
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
    Cancer research, 1956, Volume: 16, Issue:10 Part 1

    Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl

1956
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
    Cancer research, 1956, Volume: 16, Issue:10 Part 1

    Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl

1956
[Effect of glycine on liver glycogen content in normal and tumor-bearing mice following administration of medinal].
    Biulleten' eksperimental'noi biologii i meditsiny, 1956, Volume: 42, Issue:12

    Topics: Animals; Barbital; Barbiturates; Glycine; Glycine Agents; Glycogen; Glycogenolysis; Liver; Liver Gly

1956
The exchangeability of glycine accumulated by carcinoma cells.
    The Journal of biological chemistry, 1957, Volume: 225, Issue:1

    Topics: Fabaceae; Glycine; Neoplasms

1957
In vitro studies with antisera against tumor cell protein fractions.
    Cancer research, 1957, Volume: 17, Issue:4

    Topics: Glycine; Immune Sera; In Vitro Techniques; Neoplasm Proteins; Neoplasms; Proteins

1957
Concentration work and energy dissipation in active transport of glycine into carcinoma cells.
    The Journal of biological chemistry, 1957, Volume: 228, Issue:1

    Topics: Biological Transport, Active; Fabaceae; Glycine; Neoplasms

1957
Purine metabolism in mouse ascites tumor cells. 1. Effect of performed purines on in vitro incorporation of glycine-2-C14.
    Cancer research, 1958, Volume: 18, Issue:5

    Topics: Animals; Ascites; Carcinoma, Ehrlich Tumor; Glycine; In Vitro Techniques; Metabolic Networks and Pat

1958
Effects of various steroids and metabolic inhibitors on the incorporation of glycine-2-C 14 into total proteins and nucleic acids of normal and malignant lymphocytes in vitro.
    The Journal of biological chemistry, 1958, Volume: 233, Issue:5

    Topics: Encephalomyelitis; Glycine; Humans; In Vitro Techniques; Lymphocytes; Metabolism; Neoplasms; Nucleic

1958
Effect of cancer and fasting on oxidation of labeled acetate, glucose and glycine to C1402.
    The American journal of physiology, 1959, Volume: 196, Issue:2

    Topics: Acetates; Carbohydrate Metabolism; Carbon Dioxide; Fasting; Glucose; Glycine; Neoplasms; Oxidation-R

1959
Protein turnover in glycine-C14-labelled Landschütz Ascites tumor cells.
    Experientia, 1959, Mar-15, Volume: 15, Issue:3

    Topics: Animals; Ascites; Carcinoma, Ehrlich Tumor; Glycine; Neoplasms; Proteins; Proteolysis

1959
In vitro uptake of 14C labelled glycine by the cells of pleural and peritoneal fluid.
    British journal of cancer, 1959, Volume: 13, Issue:1

    Topics: Ascitic Fluid; Glycine; In Vitro Techniques; Neoplasms; Peritoneum; Pleura

1959
The effects of alkylating agents on the incorporation of glycine-1-C14 into tissue proteins in vitro.
    Cancer research, 1960, Volume: 20

    Topics: Alkylating Agents; Antineoplastic Agents; Glycine; In Vitro Techniques; Neoplasms; Proteins

1960
[Relation between cholinesterase activity and incorporation of amino acids into proteins. II. Incorporation of C14-labeled glycine into homogenized tissue of tumor homo- and heterografts under the influence of acetylphosphate].
    Acta biologica et medica Germanica, 1960, Volume: 5

    Topics: Acetylcholine; Amino Acids; Animals; Biochemical Phenomena; Cholinesterases; Glycine; Heterografts;

1960
The effect of glycine transport on potassium fluxes in the Ehrlich mouse ascites tumor cell.
    The Journal of biological chemistry, 1961, Volume: 236

    Topics: Animals; Ascites; Carcinoma, Ehrlich Tumor; Glycine; Ion Transport; Mice; Neoplasms; Potassium

1961
The effects of uncoupling agents on the uptake and incorporation of glycine by transplantable tumors.
    Cancer research, 1961, Volume: 21

    Topics: Antimetabolites; Glycine; Neoplasm Transplantation; Neoplasms; Uncoupling Agents

1961
Isolated cells: normal and tumor. III. Effects of bathing media upon intracellular uptake of glycine and upon protein synthesis.
    Cancer research, 1960, Volume: 20

    Topics: Cytoplasm; Glycine; Neoplasms; Protein Biosynthesis; Proteins

1960
Incorporation of Zn-65 in the sub-cellular fractions of the liver and spontaneously occurring mammary tumours of mice after the injection of zinc-glycine containing Zn-65.
    The Biochemical journal, 1959, Volume: 73

    Topics: Animals; Glycine; Liver; Mice; Neoplasms; Zinc

1959
[Effect of ribonucleic acid and its hydrolysates on the inclusion of glycine-1-C 14 into proteins of normal and tumor tissues].
    Biulleten' eksperimental'noi biologii i meditsiny, 1959, Volume: 48

    Topics: Biochemical Phenomena; Fabaceae; Glycine; Neoplasms; Proteins; RNA

1959
The human tumor-egg host system. II. Discovery and properties of a new antitumor agent, hadacidin.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1962, Volume: 109

    Topics: Antineoplastic Agents; Glycine; Humans; Neoplasms

1962
[Research on the modification of amino-peptidase in the blood of healthy subjects and tumor patients by D-leucine and D-leucyl-glycyl-glycine].
    Hoppe-Seyler's Zeitschrift fur physiologische Chemie, 1961, Sep-20, Volume: 325

    Topics: Endopeptidases; Glycine; Healthy Volunteers; Humans; Hydrolases; Leucine; Neoplasms; Oligopeptides;

1961
Biochemical studies of the division cycle of mammalian cells: evidence for the premitotic period.
    Biochemical pharmacology, 1963, Volume: 12

    Topics: Animals; Cell Division; DNA; DNA, Neoplasm; Glycine; Humans; Mast Cells; Methotrexate; Neoplasms; Ne

1963
Teratogenic effect of Hadacidin (a new growth inhibitory chemical) on the rat fetus.
    The Journal of experimental zoology, 1963, Volume: 152

    Topics: Animals; Antineoplastic Agents; Congenital Abnormalities; Fetus; Glycine; Neoplasms; Rats

1963
[The action of gamma globulin antibodies on the incorporation of glycine-2-C14 into the cells of Walker and Yoshida tumors].
    Comptes rendus des seances de la Societe de biologie et de ses filiales, 1962, Volume: 156

    Topics: Animals; Antibodies; Carcinoma; Carcinoma 256, Walker; gamma-Globulins; Glycine; Humans; Neoplasms;

1962
Effects of hadacidin on human tumors grown in eggs and rats.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1962, Volume: 110

    Topics: Animals; Antineoplastic Agents; Glycine; Neoplasms; Neoplasms, Experimental; Rats

1962
[THE INCORPORATION OF C-14 LABELED GLYCINE INTO ERYTHROCYTIC REDUCED GLUTATHIONE. I. IN PATIENTS WITH MALIGNANT NEOPLASMS].
    Acta vitaminologica, 1963, Volume: 17

    Topics: Carbon Isotopes; Erythrocytes; Fabaceae; Glutathione; Glycine; Humans; Metabolism; Neoplasms

1963
PEPITASE ACTIVITIES IN TISSUES OF TUMOR-BEARING RATS.
    Cancer research, 1963, Volume: 23

    Topics: Animals; Carcinoma 256, Walker; Carcinoma, Hepatocellular; Erythrocytes; Glycine; Leucine; Liver; Li

1963
STUDIES ON AMINO ACID INCORPORATION INTO PROTEIN OF TUMORS INDUCED BY ROUS SARCOMA VIRUS AND HYPERPLASIA INDUCED BY FOWL POX VIRUS IN CHORIOALLANTOIC MEMBRANE OF CHICKEN EMBRYOS.
    Cancer research, 1963, Volume: 23

    Topics: Amino Acids; Animals; Avian Sarcoma Viruses; Chick Embryo; Chickens; Chorioallantoic Membrane; Enzym

1963
[CONTRIBUTION TO THE STUDY OF RIBONUCLEOPROTEINS OF NORMAL AND NEOPLASTIC TISSUES].
    Comptes rendus hebdomadaires des seances de l'Academie des sciences, 1963, Nov-04, Volume: 257

    Topics: Alanine; Arginine; Aspartic Acid; Chemical Phenomena; Chemistry; Glutamates; Glycine; Isoleucine; Le

1963
[ACTION OF METABOLIC INHIBITORS ON ENERGY METABOLISM AND ON PROTEIN SYNTHESIS OF TUMOR AND EMBRYONAL CELLS].
    Archivio per le scienze mediche, 1963, Volume: 116

    Topics: Adenosine Triphosphate; Amino Acids; Antimetabolites; Carcinoma, Hepatocellular; Cell Biology; Chick

1963
TRANSAMIDINASE ACTIVITIES IN VITRO OF KIDNEYS FROM TUMOR-BEARING MICE AND RATS FED DIETS SUPPLEMENTED WITH PROTEIN OR CERTAIN AMINO ACIDS.
    Cancer research, 1964, Volume: 24

    Topics: Amidinotransferases; Amino Acids; Animals; Arginine; Blood Chemical Analysis; Carcinoma 256, Walker;

1964
A TRANSPORT SYSTEM SERVING FOR MONO- AND DIAMINO ACIDS.
    Proceedings of the National Academy of Sciences of the United States of America, 1964, Volume: 51

    Topics: Amino Acids; Aminobutyrates; Aminoisobutyric Acids; Arginine; Asparagine; Carbon Isotopes; Carcinoma

1964
CHROMOSOMAL ABERRATIONS INDUCED BY HYPONITRITE AND HYDROXYLAMINE DERIVATIVES.
    Journal of the National Cancer Institute, 1964, Volume: 32

    Topics: Antineoplastic Agents; Carcinogens; Cell Division; Chromosome Aberrations; Cricetinae; DNA; DNA, Neo

1964
FREE AMINO ACIDS OF HUMAN BREAST CANCER.
    The Nebraska state medical journal, 1964, Volume: 49

    Topics: Amino Acids; Asparagine; Aspartic Acid; Breast Neoplasms; Chromatography; Citrulline; Glutamates; Gl

1964
THE HUMAN TUMOR-EGG HOST SYSTEM. III. TUMOR-INHIBITORY PROPERTIES OF TENUAZONIE ACID.
    Cancer research, 1964, Volume: 24

    Topics: Adenocarcinoma; Antineoplastic Agents; Aspergillus; Azaserine; Carcinoma, Bronchogenic; Chick Embryo

1964
FURTHER STUDIES ON THE EFFECT OF THIOTEPA ON THE SYNTHESIS OF PROTEIN AND NUCLEIC ACIDS IN TUMOR-BEARING MICE.
    Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20

    Topics: Animals; DNA; DNA, Neoplasm; Glycine; Lymphoma, Non-Hodgkin; Metabolism; Mice; Neoplasm Proteins; Ne

1964
[THE EFFECT OF 2-DESOXYGLUCOSE ON ENERGY METABOLISM AND PROTEIN SYNTHESIS OF TUMOR CELLS AND NORMAL CELLS].
    Zeitschrift fur Krebsforschung, 1964, Feb-07, Volume: 66

    Topics: Animals; Antimetabolites; Bone Marrow; Carcinoma, Hepatocellular; Chick Embryo; Embryo, Mammalian; E

1964
INHIBITION OF DNA SYNTHESIS IN MAMMALIAN CELLS BY ACTIDIONE.
    Biochimica et biophysica acta, 1964, May-18, Volume: 87

    Topics: Adenine; Adenine Nucleotides; Anti-Bacterial Agents; Aspartic Acid; Carbon Isotopes; Carcinoma, Squa

1964
EFFECT OF DIETARY GLYCINE ON TRANSAMIDINASE ACTIVITY OF TUMOR BEARING MICE.
    Nutrition reviews, 1964, Volume: 22

    Topics: Amidinotransferases; Animals; Creatine; Creatinine; Diet; Glycine; Humans; Mice; Neoplasms

1964
RADIOAUTOGRAPHIC EVALUATION OF FREEZE-THAW BUFFERS USING NUCLEIC ACID- AND GLYCINE-RELATED SYNTHETIC SYSTEMS IN VITRO.
    Laboratory investigation; a journal of technical methods and pathology, 1964, Volume: 13

    Topics: Adenine; Autoradiography; Buffers; Dextrans; Dimethyl Sulfoxide; Glycerol; Glycine; In Vitro Techniq

1964
THE EFFECTS OF CORTISOL ON THE INCORPORATION OF GLYCINE CARBON INTO THE NUCLEIC ACIDS OF NORMAL AND MALIGNANT TISSUES.
    Acta endocrinologica, 1964, Volume: 47

    Topics: Carbon; Carbon Isotopes; Carcinoma, Hepatocellular; DNA; DNA, Neoplasm; Glycine; Hydrocortisone; Liv

1964
SALINE-SOLUBLE PREPARATIONS OF DEOXYRIBONUCLEOPROTEINS.
    Archives of biochemistry and biophysics, 1964, Jul-20, Volume: 106

    Topics: Acetates; Alanine; Aminobutyrates; Aminocaproates; Aminocaproic Acid; Animals; Cadmium; Caprylates;

1964
THE IN VIVO EFFECTS OF CORTISOL ON PROTEIN METABOLISM IN NORMAL AND MALIGNANT TISSUES.
    Archives internationales de pharmacodynamie et de therapie, 1964, Oct-01, Volume: 151

    Topics: Carcinoma, Hepatocellular; Glycine; Hydrocortisone; Liver; Liver Neoplasms; Neoplasm Proteins; Neopl

1964
[ON THE EFFECT OF ANABOLIC STEROIDS ON THE GLYCINE INCORPORATION INTO MALIGNANT TUMORS AND HOST TISSUE].
    Klinische Wochenschrift, 1964, Jun-15, Volume: 42

    Topics: Anabolic Agents; Carbon Isotopes; Glycine; Methenolone; Mice; Neoplasms; Research; Sarcoma; Sarcoma,

1964
THE ALTERATIONS OF NORMAL HUMAN EMBRYONIC CELL STRAINS AFTER CONTINUOUS CULTIVATION IN VITRO AND THEIR COMPARISON WITH CELL STRAINS OF TUMOR ORIGIN.
    Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20

    Topics: Amino Acids; Carcinoma, Squamous Cell; Fetus; Fibroblasts; Glycine; Histocytochemistry; In Vitro Tec

1964
[DIAGNOSTIC SIGNIFICANCE OF SERUM PEPTIDASE DETERMINATION IN BLASTOMATOUS DISEASES].
    Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete, 1965, Volume: 46

    Topics: Blood; Clinical Enzyme Tests; Diagnosis, Differential; Endopeptidases; Glycine; Heart Failure; Human

1965
THE EFFECTS OF 3'-DEOXYADENOSINE ON THE SYNTHESIS OF RIBONUCLEIC ACID.
    The Journal of biological chemistry, 1965, Volume: 240

    Topics: Adenine; Adenosine Triphosphate; Antimetabolites; Antineoplastic Agents; Carbon Isotopes; Carcinoma,

1965
PYRIMIDINE METABOLISM IN TISSUE CULTURE CELLS DERIVED FROM RAT HEPATOMAS. I. SUSPENSION CELL CULTURES DERIVED FROM THE NOVIKOFF HEPATOMA.
    Cancer research, 1965, Volume: 25

    Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Floxuridine; Fluorouracil; Glycine; Liv

1965
ETHIONINE CARCINOGENESIS IN THE RAT.
    The Journal of pathology and bacteriology, 1965, Volume: 89

    Topics: Carbon Isotopes; Carcinogenesis; Carcinogens; Carcinoma, Hepatocellular; DNA; DNA, Neoplasm; Ethioni

1965
HAEMATOLOGICAL EFFECTS OF IONIZING RADIATION IN CANCEROUS MICE.
    International journal of radiation biology and related studies in physics, chemistry, and medicine, 1965, Volume: 9

    Topics: Animals; Blood Volume; Bone Marrow; Carbon Isotopes; Carcinoma, Ehrlich Tumor; Cobalt Isotopes; Eryt

1965
The incorporation of glycine-2-C14 into acid soluble nucleotide purines.
    Cancer research, 1955, Volume: 15, Issue:2

    Topics: Glycine; Liver; Metabolic Networks and Pathways; Neoplasms; Nucleotides; Purines

1955
Incorporation of glycine-2-C14 into ascites tumor-cell purines as a biological test system.
    Cancer research, 1955, Volume: Suppl. 3

    Topics: Ascites; Glycine; Neoplasms; Nucleic Acids; Purines

1955
Protein turnover in a study of host-tumor relationships.
    Cancer research, 1955, Volume: 15, Issue:4

    Topics: Glycine; Neoplasms; Proteolysis

1955
The influence of amino acids and antimetabolities on glycine retention by Ehrlich ascites carcinoma cells.
    Cancer research, 1959, Volume: 19

    Topics: Amino Acids; Antimetabolites; Ascites; Glycine; Neoplasms

1959
Track autoradiographic study of the 14C-2-glycine incorporation into the Ehrlich ascites carcinoma cells.
    Gan, 1959, Volume: 50

    Topics: Ascites; Autoradiography; Biochemical Phenomena; Glycine; Neoplasms

1959
Hadacidin, a new growth-inhibitory substance in human tumor systems.
    Biochemistry, 1962, Volume: 1

    Topics: Antineoplastic Agents; Glycine; Humans; Neoplasms

1962
Incorporation of labeled glycine in the proteins of tissues of normal and tumor-bearing mice.
    Cancer, 1951, Volume: 4, Issue:2

    Topics: Animals; Glycine; Mice; Neoplasms; Proteins

1951
Tracer studies on the metabolism of the Gardner lymphosarcoma. I. The uptake of radioactive glycine into tumor protein.
    Cancer research, 1951, Volume: 11, Issue:7

    Topics: Glycine; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Neoplasms; Radioactive Tracers; Sarcoma

1951
Tracer studies on the metabolism of the Gardner lymphosarcoma. III. The rate of radioactive alanine and glycine uptake into the protein of lymphosarcoma cells and normal spleen cells.
    Cancer research, 1951, Volume: 11, Issue:7

    Topics: Alanine; Glycine; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Radioactive Tracers; Sarcoma; Spleen

1951
The action of glycine on the liver glycogen of fasting mice, normal and adrenalectomized.
    The Journal of endocrinology, 1951, Volume: 7, Issue:4

    Topics: Adrenal Gland Neoplasms; Adrenal Glands; Animals; Fasting; Glycine; Glycine Agents; Liver; Liver Gly

1951
In vivo studies on incorporation of glycine-2-C14 into proteins and nucleic acid purines.
    Cancer research, 1952, Volume: 12, Issue:2

    Topics: Glycine; Neoplasms; Nucleic Acids; Proteins; Purines

1952
Novel peptide ligands for integrin alpha 4 beta 1 overexpressed in cancer cells.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:10

    Topics: Alanine; Animals; Binding Sites; Cell Adhesion; Cell Line; Cell Line, Tumor; Cell Proliferation; CHO

2004
Cancer incidence among glyphosate-exposed pesticide applicators in the Agricultural Health Study.
    Environmental health perspectives, 2005, Volume: 113, Issue:1

    Topics: Adult; Aged; Agriculture; Cohort Studies; Female; Glycine; Glyphosate; Herbicides; Humans; Incidence

2005
Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dioxanes; Enzyme Inhibitors; Glycine; Humans; Hypo

2006
99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours.
    European journal of nuclear medicine and molecular imaging, 2007, Volume: 34, Issue:8

    Topics: Animals; Carcinoma, Medullary; Cysteine; Edetic Acid; Gastrins; Gene Expression Regulation, Neoplast

2007
Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-b-poly(epsilon-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells.
    Biomacromolecules, 2007, Volume: 8, Issue:3

    Topics: Aldehydes; Arginine; Aspartic Acid; Cell Line, Tumor; Drug Delivery Systems; Glycine; Humans; Lacton

2007
Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.
    Toxicological sciences : an official journal of the Society of Toxicology, 2007, Volume: 98, Issue:1

    Topics: Animals; Carcinogenicity Tests; Carcinogens; Dose-Response Relationship, Drug; Female; Glycine; Hypo

2007
Technetium-99m-labeling and synthesis of thymidine analogs: potential candidates for tumor imaging.
    Bioorganic & medicinal chemistry letters, 2007, Jun-15, Volume: 17, Issue:12

    Topics: Chelating Agents; Edetic Acid; Glycine; Isotope Labeling; Ligands; Magnetic Resonance Imaging; Model

2007
Distinct effects of the recurrent Mlh1G67R mutation on MMR functions, cancer, and meiosis.
    Proceedings of the National Academy of Sciences of the United States of America, 2008, Mar-18, Volume: 105, Issue:11

    Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Cell Line; Chromosomes; Cisplatin; DNA Dam

2008
Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor.
    Chembiochem : a European journal of chemical biology, 2008, Jun-16, Volume: 9, Issue:9

    Topics: Angiogenesis Inhibitors; Aza Compounds; Binding Sites; Drug Design; Glycine; Integrin alpha5beta1; I

2008
Metabolic functions of myo-inositol. V. Utilization of glycine and serine in nucleotide and nucleic acid biosynthesis by inositol-deficient KB cells.
    The Journal of biological chemistry, 1967, Jun-10, Volume: 242, Issue:11

    Topics: Carbon Isotopes; Culture Techniques; Glycine; Humans; Inositol; Mouth Neoplasms; Neoplasms; Nucleic

1967
Metabolic functions of myo-inositol. VI. Impairment of amino acid transport in KB cells caused by inositol deficiency.
    The Journal of biological chemistry, 1967, Jun-10, Volume: 242, Issue:11

    Topics: Aminoisobutyric Acids; Carbon Isotopes; Culture Techniques; Glycine; Humans; Inositol; Kinetics; Mou

1967
Whole-body protein turnover in metabolically stressed patients and patients with cancer as measured with [15N] glycine.
    Biochemical medicine, 1983, Volume: 30, Issue:1

    Topics: Adolescent; Adult; Aged; Female; Glycine; Humans; Liver; Liver Function Tests; Male; Middle Aged; Ne

1983
Serum amino acids in weight-losing patients with cancer and tuberculosis.
    European journal of cancer & clinical oncology, 1983, Volume: 19, Issue:6

    Topics: Adult; Amino Acids; Body Weight; Citrulline; Female; Glycine; Humans; Lung Neoplasms; Male; Middle A

1983
Whole body protein synthesis and turnover in normal man and malnourished patients with and without known cancer.
    Annals of surgery, 1981, Volume: 194, Issue:2

    Topics: Adult; Aged; Body Weight; Fasting; Female; Glycine; Humans; Male; Middle Aged; Neoplasms; Nitrogen I

1981
Fluorescence high-performance liquid chromatographic determination of free and conjugated bile acids in serum and bile using 1-bromoacetylpyrene as a pre-labeling reagent.
    Journal of chromatography, 1983, Jan-14, Volume: 272, Issue:1

    Topics: Bile; Bile Acids and Salts; Chromatography, High Pressure Liquid; Fluorescent Dyes; Glycine; Humans;

1983
Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 ant
    Human pathology, 1994, Volume: 25, Issue:3

    Topics: Antigens, Neoplasm; Biomarkers, Tumor; Cell Nucleus; Formaldehyde; Glycine; Humans; Immunohistochemi

1994
Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer.
    Cancer research, 1993, Feb-01, Volume: 53, Issue:3

    Topics: Adolescent; Adult; Alleles; Arginine; Base Sequence; Child; Child, Preschool; Exons; Family Health;

1993
Hybridization of a 99Tcm-labelled oligodeoxynucleotide to CAPL RNA.
    Nuclear medicine communications, 1998, Volume: 19, Issue:8

    Topics: Base Sequence; Calcium-Binding Proteins; Chelating Agents; Female; Glycine; Humans; Neoplasms; Nucle

1998
The crystal structure of human cytosolic serine hydroxymethyltransferase: a target for cancer chemotherapy.
    Structure (London, England : 1993), 1998, Sep-15, Volume: 6, Issue:9

    Topics: Binding Sites; Catalytic Domain; Crystallography, X-Ray; Cytosol; Dimerization; DNA Replication; Dru

1998
Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene.
    Oncogene, 2001, Jan-04, Volume: 20, Issue:1

    Topics: Amino Acid Sequence; Arginine; Aspartic Acid; Breast Neoplasms; Female; Glutamic Acid; Glycine; Huma

2001
Isolation and identification of urinary beta-aspartyl dipeptides and their concentrations in human urine.
    Journal of biochemistry, 1978, Volume: 84, Issue:3

    Topics: Adolescent; Adult; Aged; Aging; Aspartic Acid; Child; Dipeptides; Female; Glutamates; Glycine; Human

1978
Characterization of a Gly19-->Val mutant of ram p25, a low Mr GTP-binding protein: loss of GTP/GDP-binding activity in the mutated ram p25.
    Biochemical and biophysical research communications, 1992, Nov-30, Volume: 189, Issue:1

    Topics: Amino Acid Sequence; Base Sequence; Cloning, Molecular; Escherichia coli; Genes, ras; Glycine; GTP P

1992
Effect of the route of nutrient administration on whole-body protein kinetics in man.
    Metabolism: clinical and experimental, 1987, Volume: 36, Issue:10

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Energy Intake; Fasting; Female; Food, Formulat

1987
Tracer priming in human protein turnover studies with [15N]glycine.
    Biochemical medicine, 1985, Volume: 34, Issue:2

    Topics: Ammonia; Glycine; Humans; Infusions, Parenteral; Injections, Intravenous; Kinetics; Mathematics; Met

1985
Urea inhibition of lactate dehydrogenase. A convenient routine procedure.
    Acta medica Academiae Scientiarum Hungaricae, 1970, Volume: 27, Issue:1

    Topics: Anemia; Buffers; Clinical Enzyme Tests; Glycine; Humans; Ischemia; L-Lactate Dehydrogenase; Liver; L

1970
[Clinical studies on serum leucyl glycyl glycine hydrolyzing enzyme in cancer. I].
    Naika hokan. Japanese archives of internal medicine, 1971, Volume: 18, Issue:1

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Cobalt; Edetic Acid; Electrophoresis; Female; Glycine; Hepat

1971
[Clinical studies on serum leucyl glycyl glycine hydrolyzing enzyme in cancer. II].
    Naika hokan. Japanese archives of internal medicine, 1971, Volume: 18, Issue:2

    Topics: Adult; Aged; Amino Acids; Aminopeptidases; Female; Glycine; Humans; Leucine; Leucyl Aminopeptidase;

1971
The erythrocyte plasma distribution of amino acids in health and disease.
    Clinica chimica acta; international journal of clinical chemistry, 1968, Volume: 20, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Alanine; Amino Acids; Anemia, Hemolytic; Anemia, Pernicious; Bronc

1968
Uptake of labelled amino acids into human erythrocytes in disease.
    Clinica chimica acta; international journal of clinical chemistry, 1968, Volume: 20, Issue:1

    Topics: Acute Disease; Alanine; Amino Acids; Anemia; Bronchitis; Bronchopneumonia; Carbon Isotopes; Erythroc

1968
[The aminoacetone in neoplastic tissues].
    Bollettino della Societa italiana di biologia sperimentale, 1966, Apr-30, Volume: 42, Issue:8

    Topics: Acetates; Coenzyme A; Glycine; Histocytochemistry; Neoplasms

1966